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ABSTRACT OF DISSERTATION

CLINICAL AND PATHOLOGIC SIGNIFICANCE OF INTEGRIN Į6ȕ4 EXPRESSION
IN HUMAN MALIGNANCIES
Integrins are cellular adhesion molecules that bind cells to the extracellular
matrix. The integrin Į6ȕ4, a receptor for laminins, is predominantly expressed on
epithelial cells where it is present at the basal surface adjacent to the basement
membrane. This integrin plays a critical role in maintaining normal cellular functions, yet
has also been implicated in promoting invasion and metastasis in human malignancies.
While overexpression of the integrin Į6ȕ4 has been detected in select human cancers,
the clinical significance of integrin Į6ȕ4 expression in a number of malignancies has not
been determined. The purpose of this study was to examine integrin Į6ȕ4 expression as
it relates to clinical variables and patient outcomes in tumors of the lung, breast, and
central nervous system. In order to study integrin Į6ȕ4 protein expression in patientderived tumors, tissue microarrays were constructed and sections were stained using
immunohistochemistry for the integrin ȕ4 subunit. Integrin ȕ4 mRNA levels in patientderived tumors were also examined using publicly available gene expression datasets.
Integrin ȕ4 expression was found to be elevated in lung squamous cell carcinoma, and
its overexpression was associated with venous invasion and decreased overall survival
among patients with non-small cell lung cancer. In gliomas, integrin ȕ4 was highly
expressed in glioblastomas when compared to lower grade gliomas and non-neoplastic
brain tissue. Integrin ȕ4 expression was shown to be an adverse prognostic marker in
gliomas, and furthermore, integrin ȕ4 expression was reduced in gliomas with mutations
in IDH1. In breast cancer, integrin Į6ȕ4 expression was found to be elevated in triple
negative tumors, and in one cohort, elevated integrin ȕ4 expression was associated with
HER2 overexpression. In summary, I have shown that integrin ȕ4 expression is elevated
in a number of aggressive human malignancies, and that its expression associates with
poor prognosis in these tumors.
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CHAPTER 1: INTRODUCTION*
Integrins are cellular adhesion molecules that serve as receptors for extracellular
matrix (ECM) components and select cell adhesion molecules. Named for their ability to
integrate signals from the extracellular environment to the inside of the cell, integrins are
responsible for securing cells to the surrounding adhesion molecules while amplifying
and potentiating signals from growth factor receptors and other extracellular stimuli.1
These transmembrane proteins permit cells to sense and respond to their environment
and thus play critical roles in maintaining normal cellular functions, yet have also been
implicated in promoting invasion and metastasis in human malignancies.2
Integrins are heterodimeric receptors that consist of paired α and β subunits. In
the human genome, there are 18 α and 8 β subunits that combine in a limited
combination to provide 24 integrin receptors, each with its own specificity for select ECM
or cellular adhesion proteins (for review, see

1,3

). Integrins containing the α6 subunit are

laminin receptors in which the α6 subunit can pair with either the β1 or β4 subunit. In
contrast, the integrin β4 subunit can only pair with the α6 subunit,1,2,4 thus making β4
subunit expression predictive of integrin α6β4 expression.
Integrin α6β4 is predominantly expressed on epithelial cells where it is present at
the basal surface adjacent to the basement membrane where it nucleates the formation
of hemidesmosomes. These stable adhesions are critical for the integrity of epithelial
monolayers. In contrast to this function, integrin α6β4 signaling in various cancers
promotes an invasive and metastatic phenotype. This functional change is mediated by
phosphorylation of the cytoplasmic tail of the integrin β4 subunit that releases integrin
α6β4 from hemidesmosomes and allows the integrin to promote invasive signaling
through cooperation with growth factor receptors and alteration of the transcriptome,
which in turn facilitates tumor progression.2,4-9
*ADAPTED FROM: Stewart RL, O'Connor KL. Clinical significance of the integrin α6β4 in
human malignancies. Laboratory Investigation. 2015.
1

Structure and normal function of integrin α6β4
The α6β4 integrin is a specialized integrin that is expressed in various normal
epithelia, Schwann cells and endothelial cells. The integrin β4 subunit is distinct from
other integrin subunits in that it has a particularly long cytoplasmic signaling domain.
Whereas the cytoplasmic domains of other integrin subunits are less than 50 amino
acids in length, the integrin β4 subunit is over 1000 amino acids in length.10,11 As
depicted in Figure 1.1, the cytoplasmic domain of the integrin β4 subunit is characterized
by two pairs of fibronectin type III domains, a Calxβ domain and a connecting segment.12
The fibronectin repeats and the connecting segment are necessary for hemidesmosome
assembly.13-15
At the basal surface of normal cells adjacent to the basement membrane, integrin
α6β4 binds to laminins in the ECM and facilitates stable adhesion through the formation
of hemidesmosomes. Hemidesmosomes are large adhesion complexes that anchor the
basal layer of epithelial cells to the basement membrane.13-15 In these junctions, the
α6β4 integrin nucleates the connection between cytokeratin intermediate filaments in the
cell and laminins in the basement membrane through its interactions with plectin,
collagen XVII/BP180 and BP230, as depicted in Figure 1.1B.16,17 The importance of
these junctions is highlighted by the fact that mutations in the integrin β4 gene (ITGB4)
can cause lethal forms of epidermolysis bullosa with pyloric atresia, a disorder
characterized by blistering and ulceration of the skin and mucosal tissues.18 While it has
been suggested that other integrins may be able to compensate for a loss of integrin
α6β4, studies in mouse models have demonstrated that this is not the case.19 Integrin β4
knockout mice (-/-) are born with severe epidermal blistering, exhibit widespread
separation of the epithelial-mesenchymal junction, and die shortly after birth. These
observations emphasize the importance of the integrin β4 subunit in maintaining the
integrity of the epithelial-ECM junction.19
2

Figure 1.1: Integrin α6β4 structure and hemidesmosome assembly. A) The integrin
β4 subunit only pairs with the α6 subunit. The long cytoplasmic domain of β4 is
structurally distinct from other known receptors but contains several distinct domains
including a Calx-β domain, four fibronectin type III repeats, a connecting segment and Cterminal tail. B) Integrin α6β4 nucleates hemidesmosomes by binding to multiple
hemidesmosomal associated proteins including Plectin (HD1), BP180 (also known as
BPAG2 or collagen XVII) and BP230 (also known as BPAG1).
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Hemidesmosomes

are

dynamic

structures.

During

wound

healing,

hemidesmosomes must be dismantled to allow the leading edge cells to migrate into the
wound.14,20 This functional change is mediated by phosphorylation of the cytoplasmic tail
of the integrin β4 subunit that releases integrin α6β4 from hemidesmosomes. This
process occurs through stimulation by growth factor receptors such as the epidermal
growth factor receptor (EGFR), and by direct phosphorylation of the integrin β4
cytoplasmic tail by protein kinase C.7,8,21 Upon release from hemidesmosomes, integrin
α6β4 relocalizes from the keratin cytoskeleton to the actin cytoskeleton.22 When bound
to F-actin, the integrin α6β4 signaling domain promotes the formation of motility
structures, such as filopodia and lamellae, by cooperating with growth factor receptors
and stimulating key signaling pathways6,7,22-24 that in turn facilitate migration and wound
closure.
Integrin α6β4 and hemidesmosomes are also suggested to play a role in the
contextual orientation of cells. When cells are not adhered to the proper extracellular
matrices, they will undergo a specialized form of apoptosis known as anoikis. Notably,
when caspases are activated, the β4 cytoplasmic tail is cleaved leading to apoptosis.25,26

Integrin α6β4 signaling in malignant cells
Release of integrin α6β4 from hemidesmosomes can lead to altered signals that
promote tumor cell growth, invasion and metastasis.2,4-9 Under conditions where
hemidesmosomes are disassembled, integrin α6β4 binding directly to laminin has been
shown to activate both phosphoinositide 3-OH kinase (PI3K) and RhoA small
GTPases.6,24 Alternatively, the integrin can cooperate with multiple different growth factor
receptors including those in the EGF receptor family (ErbB-1,2,3), c-Met, Ron, LPA1 and
LPA223,27-30 to enhance signaling through PI3K, AKT, MAPK and the Rho small
GTPases,6,23,24,31,32 as depicted in Figure 1.2. In cells with mutant p53, the α6β4 integrin
4

promotes cell survival through activation of AKT/PKB,31 and stimulates cell cycle
progression and proliferation by interacting with Shc to activate the Ras-MAPK
pathway.32 As shown in breast and pancreatic cancers, this integrin can promote tumor
progression through transcriptional regulation and has been shown to increase the
expression of invasive and metastatic proteins such as the epithelial to mesenchymal
transition (EMT)-associated protein S100A4 (also known as metastasin/FSP).33-35 In the
next several sections, I discuss our current understanding of how integrin α6β4 signaling
promotes a malignant phenotype with an emphasis on its impact on invasion, cell
survival and angiogenesis.

5

Figure 1.2: Cancer progression-associated signaling pathways activated by
integrin α6β4. Integrin α6β4 can activate multiple signal transduction cascades either
directly by binding its ligand laminin or by amplifying signals from multiple growth factors.
Enhanced signaling through these pathways contributes to tumor progression in terms of
enhanced proliferation, cell survival, invasion and metastasis. Notably, integrin α6β4 can
act as a tumor suppressor by promoting apoptosis in the presence of a wild-type p53.
For this reason, integrin α6β4 is often overexpressed primarily in tumor types where p53
mutations are prominent such as pancreatic and basal-like breast cancers.

6

Invasive signaling functions
The finding that integrin α6β4 mediates stable adhesive complexes that anchor
cells to the basement membrane would seem to argue against the participation of
integrin α6β4 in cell migration. Despite this apparent contradiction, numerous studies
have confirmed that integrin α6β4 is responsible for promoting migratory and invasive
behavior in carcinoma cells. A potential explanation for this phenomenon comes from its
normal role in wound healing,14,20,36 as described above.
Early studies in colon and breast carcinoma lines demonstrated that expression
of integrin α6β4 contributes to tumor cell invasiveness.6,9,37 These studies lead to the
pivotal discovery that integrin α6β4 can promote invasive properties in carcinoma cells
by activating the PI3K pathway,6 a signaling pathway that is now well known for its role
in promoting carcinoma progression.38 Notably, this was the first time that PI3K had
been implicated in carcinoma invasion. This finding was subsequently confirmed in a
number of additional reports,39-41 although the exact mechanism by which integrin α6β4
activates PI3K initially remained elusive. The cytoplasmic domain of the integrin β4
subunit does not contain a consensus-binding motif for the regulatory subunit of PI3K,
making direct activation of this pathway by integrin β4 subunit unlikely.4,6,42 One
mechanism for integrin β4-mediated activation of PI3K was found to involve insulin
receptor substrate-1 and -2 (IRS-1 and IRS-2), which act as signaling intermediates that
facilitate integrin α6β4-mediated PI3K activation.42 Ligation of integrin α6β4 promotes
phosphorylation of IRS-1 and IRS-2, leading to subsequent activation of PI3K.42 An
additional mechanism has been described wherein integrin α6β4 cooperates with ErbB-2
to promote PI3K-dependent invasion.39 Finally, integrin α6β4 has been shown to localize
to lipid rafts in the plasma membrane, which may allow it to activate PI3K by facilitating
close interactions with other receptor tyrosine kinases.4,40
The involvement of integrin α6β4 in cell polarization and the formation of F-actin
7

rich motility structures such as filopodia and lamellae lead to investigations into the Rho
family of small GTPases. The Rho family of small GTPases largely control the
reorganization of the actin cytoskeleton needed for cell motility.43 Initial studies by Shaw
and colleagues on the activation and function of PI3K in invasion found that the small
GTPase Rac1 was required for invasion downstream of PI3K,6 a finding confirmed by
others.44 Notably, integrin α6β4 can cooperate with growth factor receptors45 and other
integrins23 to activate Rac1. Further studies examining the impact of integrin α6β4 on
migration and invasion found that integrin α6β4 increased the activity of cAMP-specific
phosphodiesterase,

thereby

resulting

in

decreased

cAMP

concentrations

and

subsequent RhoA activation.9,24 The activation of RhoA downstream of integrin α6β4
subsequently leads to the formation of RhoA-dependent membrane ruffling and lamellae
formation, as well as the generation of contraction forces that enable cell migration.24,46
Our group found that the metastasis associated protein S100A4, which is regulated by
integrin α6β435 interacts with Rho effector Rhotekin to promote cell membrane ruffling.47
Notably, the traditional function for RhoA is the generation of stress fibers rather than
membrane ruffling, suggesting that integrin α6β4 can change the function of RhoA to
facilitate tumor invasion.
Integrin α6β4 amplifies signaling through multiple receptor tyrosine kinases and
G-protein coupled receptors in order to promote tumor cell proliferation and invasion.
Notably, cooperative signaling has been identified between integrin α6β4 and multiple
members of the EGFR family. EGFR and integrin α6β4 have also been shown to colocalize at the leading edge of carcinoma cells subjected to EGF stimulation, and
notably, their interaction is inhibited by curcumin, a compound present in turmeric.48
Integrin α6β4 has also been shown to associate with ErbB-2 in multiple breast
carcinoma cell lines,30,49 though reports are conflicting as to whether integrin α6β4
expression correlates with ErbB-2 protein overexpression in patient-derived carcinoma
8

tissues.50-53 Using a mouse model of ErbB-2 mediated tumorigenesis, loss of integrin β4
signaling was shown to reduce breast tumor invasive growth and metastasis, and
deletion of the integrin β4 signaling domain was shown to enhance the efficacy of
ErbB2-targeted therapy.27 This study also demonstrated that the integrin β4 subunit
forms a complex with ErbB-2 and amplifies ErbB-2 signaling. In addition, integrin α6β4
has been shown to regulate the expression of ErbB-2 by influencing its translation.54
These findings are particularly notable as ErbB-2 amplification promotes invasion in
human malignancies such as breast carcinoma, and is associated with aggressive
behavior.55,56
While an interaction with ErbB-2 may be necessary in order for integrin α6β4 to
activate PI3K mediated invasion in select cell types, ErbB-2 lacks a consensus-binding
site for the regulatory subunit of PI3K. Furthermore, ErbB-2 must dimerize with an EGFR
family member in order to function.30,57 A potential solution to this issue was suggested
by the finding that integrin α6β4-mediated PI3K activation is dependent on ErbB-2/ErbB3 heterodimerization.30 The ErbB-2/ErbB-3 heterodimer is a strong activator of PI3K,30,58
and the ErbB-3 cytoplasmic domain contains binding sites for the regulatory subunit of
PI3K.59 Integrin α6β4 can regulate the expression of ErbB-3, leading to an increase in
ErbB-2/ErbB-3 heterodimerization and subsequent PI3K activation,30 and notably, a
positive association has been identified between integrin α6β4 and ErbB-3 expression in
patient-derived tumors.51
Integrin α6β4 can also cooperate with c-Met, a receptor tyrosine kinase that is
activated by the hepatocyte growth factor (HGF).28,29 In one study, integrin α6β4 was
shown to form a direct complex with c-Met that promotes HGF dependent invasion.28
Additional studies have shown that while an interaction with integrin α6β4 may contribute
to c-Met dependent invasion, integrin α6β4 and c-Met are also able to promote invasion
independently.29 Evidence for a physical association between integrin α6β4 and c-Met is

9

controversial;4,29 however, this does not preclude the probability that integrin α6β4 can
cooperate with c-Met without physical association.
Ron (“recepteur d'origine nantais”), a tyrosine kinase receptor closely related to
c-Met, has been shown to form a complex with integrin α6β4 that induces
hemidesmosome disassembly and the relocation of integrin α6β4 to motility
structures.36,60 Further studies have shown that Ron activation is important in pancreatic
carcinoma progression,61,62 and have confirmed that Ron interacts with the integrin β4
subunit in this setting to disrupt the association between integrin β4 and plectin.60

Cell survival and apoptosis
Integrin a6β4 promotes either cell survival or apoptosis, depending on the cellular
context. In normal epithelia, integrins are critical to maintaining cellular growth and
survival as long as they maintain proper contact with the ECM.63 If anchorage to the
ECM is lost, the subsequent loss of integrin signaling can inhibit cell growth and promote
a specialized form of apoptosis referred to as anoikis.63 While tumor suppressive
functions of the integrin β4 subunit have been identified in bladder,64 colon,65 and breast
carcinoma66 cell lines, a number of additional studies have indicated that the β4 integrin
promotes cell survival.19,41,66-68 This dichotomy appears to hinge on the expression and
mutation status of the p53 tumor suppressor.
Early experiments demonstrated that expression of the integrin β4 subunit in the
colon cancer cell line RKO led to increased apoptosis, thus lending support to the notion
that integrin α6β4 functions as a tumor suppressor.65 Conversely, expression of the β4
subunit was unable to induce apoptosis in the cell line MDA-MB-435.69 The Mercurio
group investigated the mechanism underlying this apparent contradiction and observed
that the RKO and MDA-MB-435 cell lines differed in their p53 mutation status. While
RKO cells harbor a wild-type p53, the MDA-MB-435 cell line expresses mutant p53.69
10

This group demonstrated that integrin α6β4 can trigger apoptosis through p53 activation
in cells harboring wild-type p53;69 however, in carcinoma cells deficient in p53, integrin
α6β4 promotes cell survival by activating AKT/PKB31,69 and through translational
regulation of VEGF expression.68 These findings suggest that tumors expressing high
levels of integrin α6β4 in conjunction with loss of p53 function are resistant to apoptosis
and will therefore display a more aggressive clinical course. Interestingly, an association
between p53 mutations and integrin α6β4 overexpression is present in a number of
aggressive human malignancies, including basal-like breast cancer, head and neck
squamous cell carcinoma, and pancreatic ductal adenocarcinoma.50,70-76

Angiogenesis
In addition to promoting invasive properties in carcinoma cells, the integrin α6β4
can stimulate invasion and migration of endothelial cells, processes that are necessary
for pathologic angiogenesis5 (for review, see

77,78

). Studies using knockout mice carrying

a deletion in the signaling domain of the integrin β4 subunit displayed reduced
angiogenesis in a retinal neovascularization model, and developed smaller and less
vascularized tumors after subcutaneous implantation.5 The same study demonstrated
that the integrin β4 subunit could promote both bFGF- and VEGF-induced angiogenesis
by enhancing signaling through ERK and NF-κB.

The role of α6β4 in transcriptional regulation
Integrin α6β4 regulates the expression of molecules important for carcinoma
invasion and metastasis. The best studied of these include NFAT1, NFAT5, S100A4,
ErbB-2, ErbB-3 and autotaxin. The NFATs, or Nuclear Factors of Activated T-cells, are
transcriptionally regulated by the α6β4 integrin and drive carcinoma invasion.33 As
shown in breast cancer, integrin α6β4-mediated upregulation of NFAT1 leads to
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increased expression of autotaxin (ENPP2), an enzyme that acts as a motility factor by
promoting LPA production.34,79 Integrin α6β4 can also regulate the expression of ErbB-2
and ErbB-330,54 as mentioned above.
Interestingly, expression of the α6β4 integrin in MDA-MB-435 cells leads to
altered expression of over 500 genes.35 One of the most regulated and clinically relevant
of these genes is S100A4, a calcium binding protein also known as metastasin-1.80
S100A4 promotes tumor metastases80 and is regulated by integrin α6β4 through NFAT5
activation in conjunction with DNA demethylation of the S100A4 promoter.35 S100A4
interacts with Rhotekin to promote the formation of an S100A4/Rhotekin/RhoA complex,
thus allowing RhoA to promote invasion through membrane ruffling.47 Integrin α6β4 has
also been shown to negatively regulate the expression of miR-92ab and miR-99ab/100
miRNA families that impact target genes implicated in promoting cell motility.81

Integrin α6β4 expression in human malignancies
Integrin α6β4 was originally identified as a tumor progression antigen by two
separate groups, one who termed it tumor-specific antigen-180 (TSP-180)82 and the
other who referred to it as the A9 complex.83 Subsequently, the TSP-180 and A9
complexes were shown to be identical to integrin α6β4.84,85 During the invasive process,
integrin α6β4 is released from hemidesmosomes where it can then participate in many
of the most aggressive properties of advanced carcinomas. Immunohistochemical
staining in patient-derived tissues confirms that in many cancers, expression and
localization of integrin α6β4 are altered (as demonstrated in Fig. 3).
Studies examining integrin β4 expression in patient-derived tissue, in some
cancer types, have obtained conflicting results. It is unclear whether these contradictory
findings relate to sample size, cancer subtype examined or the method of detection.
Some investigators have reported inconsistent immunohistochemical staining for integrin
12

β4 in formalin-fixed, paraffin embedded tissue sections.53 Our group found that
immunohistochemistry for the integrin β4 subunit is particularly sensitive to the antigen
retrieval process.72 In addition, different studies have used a variety of clonal antibodies
to detect integrin β4 expression, which may partially explain the variability in staining
patterns that has been reported. Below, I discuss the clinical associations of integrin
α6β4 in various human malignancies, noting where there is disagreement in the
literature.

13

Figure 1.3: Altered localization of integrin α6β4 expression in invasive breast
carcinoma. In a dilated duct with benign columnar cell change (left), integrin α6β4 is
expressed in myoepithelial cells surrounding the duct, but is absent in luminal cells.
Adjacent nests of invading carcinoma cells (right) display elevated expression of the
integrin β4. Immunohistochemical staining was performed using the 439-9B antibody as
described in Chapter 2. Brown staining represents positive expression of the integrin β4.
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0DOLJQDQFLHVZLWKVWURQJHYLGHQFHWKDWLQWHJULQȕH[SUHVVLRQLVSDWKRORJLFDOO\
VLJQLILFDQW
Breast cancer
In breast cancer, integrin β4 overexpression is associated with aggressive
behavior

and

poor

prognosis.

Given

the

challenges

described

with

immunohistochemistry, gene expression profiling provides an excellent alternative that
allows for quantitative assessment of integrin β4 expression. One study used gene
expression profiling and immunohistochemistry of tissue microarray (TMA) sections to
demonstrate that integrin β4 is overexpressed in basal-like breast cancer.50 This finding
is particularly notable as basal-like breast cancer is an aggressive subtype that is
associated with a notoriously poor prognosis.71 This group further developed a 65-gene
signature that included the top genes whose expression was found to correlate with that
of integrin β4. This integrin “β4 signature” was shown to be a prognostic indicator that
could predict both decreased survival and decreased time to recurrence in four breast
cancer cohorts.50 In other studies, integrin β4 mRNA expression was found to positively
correlate with nuclear grade and tumor size,53 and elevated integrin α6β4 protein
expression has been found to associate with decreased survival.86 Co-expression of
integrin α6β4 and Net1, a RhoA guanine nucleotide exchange factor, has also been
associated with decreased distant metastasis-free survival.52
In contrast to the findings described above, a number of early reports indicated
that integrin β4 expression is absent or rare in breast cancers. This observation may be
due to difficulties with immunohistochemistry on frozen specimens, or may be related to
the fact that these studies were performed before the modern sub-classification of breast
cancers was developed. As integrin β4 overexpression is more frequent in triple negative
breast cancers (TNBCs), and these tumors represent a minority of breast cancers, these
studies may not have included an adequate number of TNBCs to detect integrin β4
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overexpression. Two of these early investigations report that integrin β4 expression was
absent in all invasive breast carcinomas examined,82,87 while another found strong
integrin β4 staining in only a small subset of breast tumors.88 Others have reported that
integrin β4 is redistributed over the cell surface in select breast carcinomas.89 Integrin
β4 expression in ductal carcinoma in situ (DCIS) is also reportedly rare, with expression
identified in only 20% of cases in one study.90 According to another report, integrin β4
expression was absent in the neoplastic cells of DCIS and detected only in residual
myoepithelium.87 Given more recent evidence using gene expression profiling, it is
reasonable to conclude that at least a certain subset of breast tumors overexpress
integrin β4, including basal-like breast cancers.

Bladder cancer
Studies investigating integrin β4 expression in bladder cancer demonstrate that it
is overexpressed in a proportion of transitional cell carcinomas, and suggest its use as a
prognostic marker. An early study reported that in normal urothelium integrin α6β4 is
expressed in the basal layer of urothelial cells where this expression is highly polarized
and localized to the lamina propria junction. The authors then examined integrin α6β4
expression in ten low stage bladder cancers, where they found increased, non-polarized
expression in 80% of tumors.91 A subsequent study by the same group examined
integrin α6β4 expression in bladder tumors from 57 patients; each case was categorized
as having negative, weak, or strong expression of integrin α6β4, where weak was
defined as expression that most closely resembled that of normal urothelium.92 They
found that patients with weak integrin α6β4 expression had improved survival compared
to patients with either strong or negative expression.92 Another study examined integrin
β4 expression in a cohort of patients with non-muscle invasive bladder cancer and found
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that integrin β4 expression levels were an independent predictor of intravesical
recurrence after transurethral resection.93

Cervical cancer
Integrin β4 expression in cervical lesions has been examined primarily in cervical
intraepithelial neoplasia (CIN) and squamous cell carcinoma. Multiple reports have
confirmed that the integrin β4 is strongly expressed in invasive squamous cell
carcinomas of the cervix.94-96 Interestingly, integrin β4 expression positively correlates
with the degree of squamous atypia in CIN.94,95 In a study of cervical biopsies from 35
patients, integrin β4 expression was present only in cells of the basal and parabasal
layers of normal ectocervical mucosa, and this pattern was maintained in flat
condylomas, hyperplastic epithelium, and in CIN I lesions.94 Interestingly, in CIN II-III,
integrin β4 expression was present throughout the entire thickness of the epithelium,
with strong staining observed toward the superficial surface. Furthermore, expression of
integrin β4 was identified in 90% of cervical carcinomas studied, where expression was
diffusely present in the invasive nests.94
A larger study investigated integrin β4 expression in 40 cervical biopsies. The
authors describe that in normal ectocervical mucosa, integrin β4 expression was
localized to the basal aspect of cells in the basal layer of epithelium.95 They found that in
CIN, expression of the integrin β4 followed the distribution of atypia: for example, in CIN
II, β4 was expressed throughout the lower 2/3 of the epithelial thickness, while in CIN III,
β4 was expressed throughout the full epithelial thickness. These findings suggest that
the integrin β4 may play an early role in promoting the survival and growth of preinvasive neoplasms.
A third study examined expression of the integrin β4 in 20 cases of invasive
cervical carcinoma and 23 cases of CIN III.96 The invasive cervical carcinomas included
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examples of well, moderately, and poorly differentiated squamous cell carcinoma, as
well as three endocervical adenocarcinomas. Diffuse expression of the integrin β4 was
identified in all 20 cases of invasive carcinoma. In addition, integrin β4 expression was
identified in all epithelial layers in 65% of CIN III lesions.96

Head and neck cancer
In squamous cell carcinomas of the head and neck, integrin β4 is commonly
overexpressed. An early study of 82 patients with SCC of the head and neck found that
strong expression of the UM-A9 antigen (later identified as the α6β4 integrin) was
associated with early relapse and decreased patient survival.97 In another study, integrin
β4 expression was found to be upregulated in SCCs when compared to normal
squamous mucosa, although an association was found between loss of integrin β4
expression and the presence of nodal metastases.98
Multiple studies using gene expression profiling have confirmed that integrin β4
gene expression levels are prognostically significant in SCCs of the head and neck. One
of these reports demonstrated that integrin β4 gene expression was associated with
decreased survival in a cohort of 66 patients.99 In a larger study, increased integrin β4
gene expression was associated with the presence of lymph node metastases, distant
metastases and patient death on univariate analysis, and was an independent predictor
of distant metastases on multivariate analysis.100

Lung cancer
Integrin β4 is overexpressed in non-small cell lung cancers, and expression is
particularly high in pulmonary squamous cell carcinomas. An early study investigated
expression of the integrin α6β4 in a series of patient-derived lung cancers and found
moderate to strong expression in all of the squamous cell carcinomas (N = 36) and
18

adenocarcinomas (N = 23) tested, though expression was notably absent in all (N =10)
of the small cell carcinomas examined.101 Integrin β4 expression was identified in a
number of non-small cell carcinoma cell lines (A431, A549, DG3), but was absent in the
single small cell carcinoma cell line tested (AE2).101
In a different study that included uninvolved normal lung tissue, normal alveolar
epithelial cells were found to be negative for integrin β4 expression, and instead
exhibited expression of the α1β1 and α3β1 laminin receptors. They further found that
bronchial and bronchiolar epithelium exhibited weak and inconsistent integrin β4
expression that was localized to the basement membrane interface. In squamous cell
carcinomas of the lung, integrin β4 expression was intense and localized to the tumorstroma interface.102 In this same study, integrin β4 expression was identified in large cell
carcinomas of the lung, but was found to be absent in neuroendocrine carcinomas.
Patriarca et al.103 also found that in normal bronchial epithelium, integrin β4 expression
was localized to the basal surface of cells in a linear pattern. They found strong and
extensive staining for the integrin β4 in 85% of squamous cell carcinomas (N = 20), but
found positive staining in only 25% pulmonary adenocarcinomas studied (N = 20). In a
complementary study using molecular profiling, integrin β4 was upregulated in lung
squamous cell carcinomas when compared to adenocarcinomas, and this was confirmed
using both immunohistochemistry and in-situ hybridization.104 Additional studies will be
needed to determine the clinical and prognostic significance of integrin β4 expression in
non-small cell lung cancer.

Pancreatic cancer
Integrin β4 is overexpressed in pancreatic carcinomas, and is also a marker of
poor prognosis. Using gene expression profiling, Logsdon et al. first determined that
integrin β4 is upregulated in pancreatic adenocarcinoma when compared to normal
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pancreatic tissue and chronic pancreatitis tissue samples,105 a finding that was
confirmed by others.106 In order to validate these findings, the Logsdon group performed
immunohistochemistry for the integrin β4 subunit and a number of other candidate genes
in 28 pancreatic adenocarcinomas, where they found that all cases had strong integrin
β4 expression.105 In another report, Gleason et al. found moderate to strong integrin β4
staining in 92% (N = 48) of pancreatic adenocarcinomas that were evaluated using
immunohistochemistry; they also found that in normal pancreas, integrin β4 staining was
weak and expressed only along the basement membranes of large ducts.107
Integrin β4 expression has also been studied in pancreatic intraepithelial
neoplasia, a non-invasive precursor lesion to pancreatic adenocarcinoma.108 In a
comprehensive study of pancreatic lesions, Cruz-Monserrate et al.72 determined that
integrin β4 overexpression is present in the early stages of pancreatic adenocarcinoma
development. As reported previously, they found that in normal pancreas, integrin β4
expression is localized to the interface between ductal epithelial cells and the basement
membrane.72 Upregulation of integrin β4 expression was observed in 92% (N = 113) of
pancreatic adenocarcinomas studied, and distinguished pancreatic cancer from
pancreatitis. Furthermore, overexpression and altered localization of the integrin β4 was
identified in all pancreatic intraepithelial neoplasia lesions ranging from Grade 1A to
Grade 3.72
Recently, elevated integrin β4 expression was shown to associate with reduced
overall survival among pancreatic adenocarcinoma patients (N = 134), where it was
found to have independent prognostic significance on multivariate analysis. Interestingly,
elevated integrin β4 expression was also found to correlate with a number of EMT
hallmarks, including solitary cell infiltration, reduced expression of E-cadherin, and
increased expression of vimentin.109 Pancreatic adenocarcinoma has one of the poorest
prognoses of all epithelial malignancies; the fact that integrin β4 is highly expressed in
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these tumors provides further evidence for its role in aggressive neoplasms.

Thyroid cancer
Thyroid carcinomas are unique in that they are one of the few malignancies to
exhibit neoexpression of integrin α6β4 during cancer progression. While expression of
integrin α6β4 is absent in normal and adenomatous follicular cells, strong expression
has been observed in both follicular and papillary thyroid carcinomas.110 Similar findings
have been reported using flow cytofluorometry, where expression of integrins such as
α1β1 and α6β1 was found in normal thyroid and tumor specimens, integrin α6β4
expression was found only in thyroid carcinomas and carcinoma cell lines.111 Others
have confirmed neoexpression of integrin α6β4 in thyroid carcinoma tissue112,113 and
have also found that it is expressed in anaplastic thyroid carcinoma, an aggressive and
poorly differentiated malignancy.112

0DOLJQDQFLHVLQZKLFKLQWHJULQȕH[SUHVVLRQKDVFRQWURYHUVLDORUXQGHWHUPLQHG
VLJQLILFDQFH
Colon cancer
One of the earliest studies to investigate α6β4 expression in human malignancies
found that the α6β4 integrin was expressed in colon cancer.82 However, additional
reports have been controversial. One study investigating integrin β4 expression in
colorectal carcinomas reported that integrin β4 expression was reduced during
malignant transformation.114 This group found that while expression of the integrin β4
subunit was maintained at the basal epithelial cell membrane in normal colonic mucosa
and in colonic adenomas, expression of the integrin β4 subunit was reduced or absent in
most colorectal carcinomas, but was maintained in well-differentiated colon cancer.114
Similar findings were reported in another study, where expression of the integrin β4
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subunit was reduced or absent in most colon carcinomas examined.115
A contrasting study demonstrated that integrin β4 is overexpressed in a majority
of colon carcinomas and that its expression is elevated in high stage, poorly
differentiated cancers.116 These findings are supported by subsequent work examining
integrin β4 expression in colorectal carcinomas using double immunofluorescence and
RT-QPCR, where integrin β4 protein and transcript levels were increased in colorectal
carcinoma when compared to normal tissue.117 Data from our laboratory also confirms
the observation that integrin β4 levels are particularly high in colon cancer cell lines and
patient-derived tissues (unpublished observation).

Ovarian cancer
In benign ovary, integrin β4 is basally located in surface and cyst lining
epithelium.75 One of the few studies investigating integrin β4 expression in ovarian
cancer found strong basal expression in all of the epithelial ovarian tumors studied, and
also found that integrin β4 was expressed in malignant cells within the ascitic fluid in
three out of nine cases.75 A second report found basally polarized integrin β4 expression
in normal ovary and in 40% of serous ovarian carcinomas examined. The authors further
noted that expression of both integrin α6 and β4 subunits were positively correlated with
laminin expression.74 Interestingly, serous ovarian cancer has a similar genomic profile
to basal-like breast cancer, with both subtypes displaying frequent loss of TP53, BRCA1,
and RB1, suggesting that integrin β4 may play an important role in both types of
cancer.70 Further work will be needed to fully characterize integrin β4 expression in
ovarian neoplasia and to determine how expression associates with prognosis.
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Prostate cancer
Early reports indicated that integrin β4 is downregulated in prostatic
adenocarcinoma, and in one investigation, expression of integrin β4 was absent in all
prostate cancers examined (N = 20).118 Multiple additional studies have reported that
integrin β4 expression is lost during the transition from benign epithelium to prostatic
adenocarcinoma.119-122 A potential explanation for this phenomenon is that androgen
receptor expression has been reported to cause downregulation of integrin α6β4.123 The
assertion that integrin β4 is downregulated in prostate cancer was challenged by a report
demonstrating that integrin β4 mRNA is overexpressed in a subset of prostate
carcinomas using gene expression datasets and a DNA microarray.124 The authors of
this study also investigated integrin β4 protein expression using immunohistochemistry
and found overexpression in 35% of invasive cancers and in a number of metastatic
lesions.124 More recently, a population of integrin β4 positive circulating tumor cells was
identified in the peripheral blood of patients with castration resistant prostate cancer.125
Overall, prostate cancer is one cancer in which integrin α6β4 is suggested to be
downregulated. However, given recent findings, it will be important to determine how
residual or enhanced integrin α6β4 expression, in the minority of cases that overexpress
it, associates with clinical parameters.

Tumors of the central nervous system
Expression of integrin α6β4 has not been extensively studied in glial tumors;
however, there is evidence demonstrating that integrin α6β4 is expressed in
astrocytomas, oligodendrogliomas, glioblastomas, and a number of glioma cell lines.
Integrin β4 expression has been identified in reactive astrocytes126 as well as in
subependymal glia, choroid plexus and meningothelial cells.127 One study found that
integrin β4 expression is higher in astrocytomas and glioblastomas when compared to
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benign astrocytes.126 A larger study investigated expression of the integrin β4 subunit in
a series of astrocytomas and oligodendrogliomas where they found that integrin β4
expression was slightly higher in oligodendrogliomas.128 Further studies will be needed
to determine how integrin α6β4 relates to glioma stage and prognosis.

Sarcomas
Integrin β4 overexpression has been described in high-grade osteosarcomas and
there is evidence it may play a role in promoting a metastatic phenotype by interacting
with ezrin.129 While integrin β4 is expressed in benign endothelial cells, its expression
appears to be reduced in angiosarcomas and other vascular tumors.130 Integrin β4
staining is also reportedly absent in rhabdomyosarcomas, ganglioneuroblastomas,
primitive peripheral neuroectodermal tumors and Ewing's sarcomas.131

Conclusions
Integrin β4 is commonly overexpressed in high-grade malignancies. Notably,
there is strong evidence that integrin β4 is overexpressed in tumors of the bladder,
cervix, lung, pancreas and thyroid. In addition, integrin β4 overexpression has been
identified as an adverse prognostic marker in tumors of the bladder and pancreas, and in
squamous cell carcinomas of the head and neck. The reason for these poor prognoses
stems from the ability of the integrin α6β4 to promote several key hallmarks of cancer,
including the capacity to sustain proliferative signaling, evade apoptosis, promote tissue
invasion and metastasis, and stimulate angiogenesis.
In a number of malignancies, it is still unclear whether expression of integrin β4 is
elevated or reduced. In tumors of the breast, prostate and colon, a number of studies
examining integrin β4 expression have obtained conflicting results, with some authors
reporting that integrin β4 is overexpressed and others reporting a reduction in integrin β4
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expression. These disparate findings may relate to differences in sample size, antibody
usage, tissue processing or antigen retrieval process. Because integrin β4 is highly
expressed at the basal aspect of normal epithelial cells but is redistributed over the cell
surface during malignant transformation, it may appear in some cases that integrin β4
expression is reduced. It is likely that altered localization of the α6β4 integrin and its
concurrent release from hemidesmosomes are as important in carcinoma progression as
overexpression, thus altered integrin α6β4 localization should be studied carefully in
these malignancies.

Study Uationale and Kypothesis
Our lab previously demonstrated that integrin β4 is highly expressed in
pancreatic adenocarcinomas, a tumor type with a high frequency of TP53 mutations.72
Notably, mutation or inactivation of TP53 is one mechanism that allows integrin α6β4 to
promote cell survival and amplify signaling through a number of invasive and
proliferative pathways. Integrin α6β4 can trigger apoptosis in cells harboring wild-type
TP53; however, in carcinoma cells with mutant TP53, integrin α6β4 promotes cell
survival.31,68,69 Interestingly, tumors with a high frequency of TP53 mutations (pancreatic
adenocarcinoma, basal-like breast cancer, squamous cell carcinomas of the head and
neck) tend to also display integrin β4 overexpression. In these tumor types, there is
evidence that integrin β4 expression is clinically significant and associates with a poor
prognosis. This observation may partially explain why integrin β4 expression is
prognostically significant in some, but not all tumor types.
Non-small cell lung cancer (NSCLC) and malignant gliomas are both aggressive
malignancies that have a high frequency of TP53 mutations. While preliminary studies
have investigated integrin β4 expression in these tumor types, the pathologic and
prognostic significance of

integrin β4 expression in these cancers
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remains

undetermined. I therefore sought to investigate integrin β4 expression in patient-derived
lung cancers and in malignant gliomas. In order to examine integrin β4 expression in a
large number of patient-derived tumors, I performed immunohistochemistry of tissue
microarray sections and analyzed integrin β4 gene expression using gene expression
databases.
While a number of studies have investigated integrin β4 expression in breast
cancer, the significance of integrin β4 overexpression in these tumors remains
controversial. In addition, integrin β4 expression in ductal carcinoma in situ (DCIS) and
its clinical significance has not been thoroughly investigated. For these reasons, I sought
to investigate integrin β4 expression in benign breast, DCIS, and invasive breast cancer.
Basal-like breast cancer has a high frequency of TP53 mutations and integrin β4
overexpression has previously been demonstrated in this tumor type.50 In order to study
integrin β4 expression in these aggressive tumors, a TMA enriched for TNBCs was
constructed. The hypothesis of this study is that in tumors of the lung, breast, and central
nervous system, integrin β4 overexpression associates with aggressive behavior and
reduced patient survival.
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CHAPTER 2: GENERAL MATERIALS AND METHODS
,PPXQRKLVWRFKHPLVWU\
As described previously, the integrin α6 subunit can pair with either the β1 or β4
subunit. In contrast, the integrin β4 subunit can only pair with the α6 subunit, therefore
integrin β4 subunit expression is predictive of integrin α6β4 expression.1,2,4
Immunohistochemistry was performed on formalin fixed paraffin embedded (FFPE)
tissue sections (4 μm) that had been baked at 60°C for 1 hour. First, sections were
deparaffinized by washing in xylene three times. The sections then went through three
washes each in 100% ethanol followed by 95% ethanol, each for 1 minute. Slides were
then rinsed in a water bath for three minutes. The activity of endogenous peroxidases
was blocked by placing slides in 3% hydrogen peroxide in phosphate buffered saline
(PBS, pH 7.4) (P3813) (Sigma-Aldrich, Saint Louis, MO) for 10 minutes. Slides were
then rinsed with water, and antigen retrieval was WKHQperformed by placing slides in a
container filled with 1 X Dako Target Retrieval Solution (S1699) (Dako Corporation,
Carpinteria, CA, USA), which had been brought to temperature in a steamer at 100°C.
The slides were kept at 100°C for 20 minutes, and then removed and allowed to cool for
an additional 20 minutes. After rinsing in water and 1 X PBS with 0.05% Tween-20
(PBST, pH 7.4) (P3563) (Sigma-Aldrich, Saint Louis, MO, USA), blocking was
performed using an Avidin-Biotin Blocking kit (SP-2001) (Vector Laboratories,
Burlingame, CA) according to the manufacturer’s instructions. Sections were then
blocked against non-specific binding by placing them in 1 X PBST and 0.3% casein for
30 minutes. Next, the sections were incubated with a rat monoclonal primary antibody to
the integrin β4 subunit (CD 104) (clone 439-9B; BD Pharmingen, San Jose, CA), at a
concentration of 1:200 in antibody diluent solution (S3022) (Dako Corporation). Slides
were incubated with the primary antibody for one hour at room temperature, after which
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WKH\XQGHUZHQWWKUHHULQVHVLQ3%671H[WWKHVOLGHVZHUHLQFXEDWHGZLWKDELRWLQ\ODWHG
UDW VHFRQGDU\ antibody (Vector Laboratories, Burlingame, CA) for 30 minutes at room
temperature at a concentration of 1:500 in antibody diluent solution (S3022) (Dako
Corporation). After incubation with the secondary antibody, slides were again rinsed
three times in PBST. Slides were then incubated for 20 minutes with Streptavidin HRP
(P0397) (Dako Corporation) at a concentration of 1:500 in PBS. Detection was
accomplished using a 3’3 diaminobenzidine (DAB) developer from a kit manufactured by
Dako Corporation (K3468). Sections were counterstained with Hematoxylin, rinsed in
water, and washed three times in 95% ethanol, 100% ethanol, and xylene. The slides
were then coverslipped using Cytoseal 60 mounting media (Richard-Allan Scientific,
Kalamazoo, MI). This immunohistochemistry protocol for integrin β4 staining was
developed by Cruz-Monserrate (14).
Statistical analysis
Differences between groups were analyzed using chi-square or Fisher’s exact
test for categorical variables, as appropriate. For continuous variables, two-tailed t-test,
two-tailed t-test with Welch’s correction, Mann-Whitney test, one-way ANOVA with post
hoc Tukey’s test, or Kruskal-Wallis test with Dunn's Multiple Comparison Test were
used, as appropriate. Survival differences were assessed via log-rank tests for
univariate analyses and Cox proportional hazards for multivariate. Significance was
reached when P < 0.05. Statistical analyses were performed using GraphPad software
(La Jolla, CA).
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CHAPTER 3: INTEGRIN α6β4 EXRESSION IN LUNG CANCER
,QWURGXFWLRQ
/XQJFDQFHUHSLGHPLRORJ\
Lung cancer is the leading cause of cancer-related mortality in the United States
and is a significant problem globally.132 Patients diagnosed with lung cancer have a poor
prognosis, and over 80% succumb to disease within 5 years of diagnosis.132 Lung
cancer is most often diagnosed between the ages of 40 – 70, with a peak incidence at
50 – 60 years of age.133 The state of Kentucky is severely affected by lung cancer,
having both the highest incidence and mortality rates for lung cancer in the United
States. This phenomenon is at least partially explained by the high prevalence of
tobacco use in this state.
Evidence demonstrating a link between cigarette smoking and lung cancer is
overwhelming. Exposure to cigarette smoke is responsible for approximately 80-90% of
lung cancers in the United States,134 though exposure to a number of additional agents
can also contribute to the development of lung cancer. These include uranium, asbestos,
radon, polycyclic aromatic hydrocarbons, arsenic, nickel, vinyl chloride, radiation and air
pollution.135 In the southeastern United States, occupational exposure related to coalmining may also elevate lung cancer risk.136 A small number of lung cancers develop in
never-smokers, and although rare, these tumors may be attributable to inherited
mutations such as the T790M mutation in EGFR.137,138
/XQJFDQFHUSDWKRELRORJ\
Lung cancer can be categorized into a number of groups based on histologic
features, immunophenotype and clinical behavior. Broadly, lung cancer can be divided
into two main categories: small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). SCLC is an epithelial tumor that is notable for its aggressive behavior and
neuroendocrine phenotype. It is distinct from other lung cancers in both clinical behavior
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and response to chemotherapy,135 and is often diagnosed at an advanced stage.
Morphologically, SCLC is characterized by small, round to oval cells with scant
cytoplasm (Fig. 3.1). The nuclei are hyperchromatic with finely granular chromatin,
leading to the common descriptor “salt and pepper” chromatin. SCLC exhibits
neuroendocrine differentiation, and typically expresses chromogranin, synaptophysin,
CD56, and other neuroendocrine markers.135 In accordance with their notoriously
aggressive behavior, the proliferation rate of these tumors reaches nearly 100% as
measured using Ki-67 immunohistochemistry.135 The presence of zonal necrosis is
another characteristic feature of SCLC.
The pathogenesis of SCLC includes aberrations in Notch and Hedgehog
signaling that mimic processes found in early lung development.139 Genomically, SCLC
is characterized by a high frequency of TP53 mutations, inactivation of RB, deletion of
chromosome 3 (p14-p23) and upregulation of BCL-2.139 Unfortunately, study of these
tumors is limited somewhat by the fact that pathologic material is difficult to obtain.
Because of the aggressive nature of SCLC, surgical resection is rarely attempted, and
hence, only small biopsies or fine needle aspiration specimens are available for analysis.
These factors limited the examination of integrin β4 expression in SCLC in this study.
NSCLC is the most common form of lung cancer and accounts for XSWR80% of
lung cancer diagnoses. NSCLC can be further divided into a variety of histologic
subtypes, the most common of which include adenocarcinoma (ADC), squamous cell
carcinoma (SCC) and large cell carcinoma (LCC). There are a few additional histologic
subtypes that are less frequently encountered; these include adenosquamous
carcinoma, sarcomatoid carcinoma, giant cell carcinoma, and carcinoid tumors. Although
exceedingly rare, analogues of salivary gland tumors are occasionally observed in the
lung and bronchus.
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Figure 3.1: Histologic features of SCLC and NSCLC.
SCLC demonstrating small, round to oval cells with hyperchromatic nuclei and scant
cytoplasm (A). NSCLC with eosinophilic cytoplasm, pleomorphic vesicular nuclei and
prominent nucleoli (B). Magnification = 200x, all images.
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Adenocarcinoma is the most common type of lung cancer in the United States. 133
Histologically, adenocarcinoma is characterized by glandular differentiation and the
presence of intracytoplasmic mucin.135 Poorly differentiated adenocarcinomas may lack
characteristic morphologic features thus requiring the use of immunohistochemistry to
arrive at a pathologic diagnosis. Adenocarcinomas are often positive for expression of
TTF-1, Napsin A, and CK7 by immunohistochemistry.140 Genomic alterations frequently
observed in lung adenocarcinoma include mutations in KRAS, EGFR, and TP53.135
Fusions involving ALK, ROS1, and EML4 have also been identified.141,142 Although rare,
HER2 mutations also occur in lung adenocarcinomas and clinical trials targeting these
mutations are ongoing.143
Squamous cell carcinomas (SCC) of the lung frequently display intracellular
bridges, and in well to moderately differentiated tumors, distinctive keratin pearls may be
noted.135

Poorly

differentiated

SCCs

can

often

be

distinguished

from

lung

adenocarcinoma by positive immunohistochemical staining for CK5/6, p63, and p40, and
by negative staining for TTF-1.144 SCCs have a high frequency of TP53 mutations, with
some sources reporting these mutations in greater than 80% of cases.145 Lung SCC
carries a poor prognosis and is typically treated with surgical resection, radiation and
traditional cytotoxic chemotherapy. While a number of targeted therapies have recently
been developed for the treatment of NSCLC, these agents target genomic alterations
that occur more frequently in lung adenocarcinoma, such as mutations in EGFR and
rearrangements of ALK and ROS1.146-149 Squamous cell carcinomas lack targeted
therapies and display notoriously aggressive behavior.
In carcinoma cells with mutant TP53, the integrin β4 promotes cell survival by
activating AKT.31 Interestingly, TP53 mutations and integrin β4 overexpression co-occur
in many aggressive malignancies, including basal-like breast cancer, serous ovarian
carcinoma, and pancreatic ductal adenocarcinoma.50,70-76 Given that lung SCC has a
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high frequency of TP53 mutations, I predicted that integrin β4 expression in this tumor
type would associate with aggressive behavior and poor prognosis. While preliminary
investigations into integrin β4 expression in NSCLC have been published previously, an
association has not been demonstrated between integrin β4 overexpression and clinical
outcomes.101-104 We therefore sought to investigate integrin β4 expression as it relates to
histologic subtype, clinicopathologic features and patient survival in lung cancer. Here, I
report that integrin β4 is highly expressed in lung SCC, and that its overexpression is
associated with decreased overall survival in NSCLC patients.

Materials and Methods
Lung cancer tissue microarray construction
Institutional Review Board Approval (13-0692-P6H) was obtained prior to
initiating the project. Surgical resections for NSCLC performed at the University of
Kentucky from 2006-2010 were identified using natural language searches in CoPath
(Cerner Corporation, Kansas City, MO). Cases were excluded if the primary tumor was
not of lung origin, or if adequate pathologic material was not available. A total of 216
cases were selected, including 83 adenocarcinomas, 102 squamous cell carcinomas, 12
adenosquamous carcinomas, 12 poorly differentiated carcinomas, 2 large cell
neuroendocrine carcinomas, 1 giant cell carcinoma, 1 pleomorphic carcinoma, 1
sarcomatoid carcinoma and 2 tumors with mixed histology (mixed adenocarcinoma and
large cell neuroendocrine). For each case, I reviewed the original hematoxylin and eosin
(H&E) stained slides and selected representative tumor blocks. Fresh H&E stained
sections were then cut from each selected block. These fresh sections were again
reviewed, and tumor areas were selected for inclusion in the arrays. Pathologic features
(tumor grade, tumor size, histologic type, pTNM staging, presence of lymphovascular,
venous, and pleural invasion) were abstracted from pathology records using CoPath
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(Cerner Corporation, Kansas City, MO). Treatment and outcome data were collected by
the Cancer Research Informatics Shared Resource Facility. Listing of randomly-sorted
samples for allocation into the recipient TMA blocks was generated by the MCC
Biostatistics and Bioinformatics Shared Resource Facility. Assembly of TMA blocks (12
in total) was performed by the MCC Biospecimen and Tissue Procurement Shared
Resource Facility. Three 2 mm diameter tissue cores were obtained from each tumor
specimen, which were transferred to recipient paraffin blocks using a TMArrayer
(Pathology

Devices,

Westminster,

MD).

TMA

sections

used for

integrin

β4

immunohistochemistry had interpretable tissue cores in 211/216 cases. Patient
characteristics for these 211 cases are summarized in Table 3.1.

Immunohistochemistry Scoring and Analysis
Immunohistochemistry was performed according to the protocol described in
Chapter 2. Specifically, the primary antibody (439-9B) was used at a concentration of
1:200 and the secondary antibody was used at 1:500. A semi-quantitative scale was
used to score integrin β4 expression as follows: negative (0), weak (1), moderate (2),
strong (3). Results from each of the three tissue cores were averaged to produce a final
score for each tumor. As integrin β4 was expressed at moderate (2) levels in benign
bronchial epithelium, we defined integrin β4 overexpression as an average score of ≥
2.5.

Data Mining
Multiple lung cancer gene expression datasets were analyzed for ITGB4
expression. The first of these was a NSCLC dataset generated by the Cancer Genome
Atlas Research Network (TCGA, http://cancergenome.nih.gov/) containing 155 SCC
samples and 32 ADC samples that were analyzed using a custom Agilent microarray.
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The second was a dataset generated by Hou et al. containing 91 NSCLCs and 65
adjacent normal lung samples that had been analyzed using a Human Genome U133
Plus 2.0 Array (Affymetrix, Santa Clara, CA).150 These datasets were accessed and
downloaded using The Oncomine™ Platform (Life Technologies, Ann Arbor, MI). The
UCSC Cancer Browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/) was
used to download a processed lung SCC gene expression dataset (N = 155) in order to
study

genes

correlated

with

ITGB4.145,151

In

addition,

cBioPortal

(http://www.cbioportal.org/) was used to generate a network map showing the 50 most
highly altered genes neighboring ITGB4 in the TCGA lung SCC dataset.152,153
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Table 3.1: Lung tissue microarray patient and tumor characteristics.
Patient Characteristics
Age at diagnosis, mean

63 (range 39-84)

Gender
Female
Male

88
123

(42%)
(58%)

Smoking Status
Patients with data
Smoker
Never smoker

159
154
5

(97%)
(3%)

Residence
Appalachian
Non-Appalachian
Out of state

145
59
7

(69%)
(28%)
(3%)

Vital Status
Alive
Deceased

89
122

(42%)
(58%)

81
99
31

(38%)
(47%)
(15%)

Differentiation
Well
Moderate
Poor

12
87
112

(6%)
(41%)
(53%)

AJCC Stage
I
II
III
IV
Unknown

108
37
44
13
9

(51%)
(18%)
(21%)
(6%)
(4%)

Tumor characteristics
Histology
Adenocarcinoma
Squamous cell carcinoma
Other

Total

211
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Results
Patient and tumor characteristics
The mean age at diagnosis for patients in this study was 63.4 (range 39-84), with
a median of 63 years. Lung cancer was more frequently diagnosed in males (58%) than
in females (42%). Of patients with data available on tobacco use, 97% had a smoking
history while only 3% were never smokers. Squamous cell carcinoma was the most
common histologic type and accounted for 47% of cases, while adenocarcinoma
accounted for 38% of cases. Most tumors were moderate (41%) or poorly (53%)
differentiated, with only a small number of well differentiated tumors (6%). The well
differentiated tumors tended to be bronchoalveolar carcinomas (92%). As patients with
localized disease are more frequently treated with surgical resection, there was a
predominance of American Joint Committee on Cancer (AJCC) Stage I and II cases,
with only 6% Stage IV cases.

Comparison of integrin β4 expression in benign and neoplastic lung
In an external gene expression dataset, NSCLCs were found to have elevated
integrin β4 expression when compared to normal lung tissue (Fig. 3.2A; P <0.0001).
Although normal lung tissue was not specifically selected for inclusion in the tissue
microarrays, benign bronchial epithelium was identified in a subset of tissue cores. In
pseudostratified columnar epithelium, integrin β4 was primarily expressed in basal cells
and along the basement membrane (Fig. 3.2B). Weak staining was also present at the
apical surface of ciliated columnar cells, while goblet cells and immune cells in the
bronchial epithelium were negative for integrin β4 expression. In a few cases, benign
bronchial epithelium was identified adjacent to invasive carcinoma cells. Here, integrin
β4 expression was higher in the invasive carcinoma (Fig. 3.2C-D). In addition, basal
polarization of integrin β4 expression was lost in invasive carcinoma.
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Expression and localization of the integrin β4 in NSCLC
Integrin β4 expression was found to be highly variable in NSCLCs: some cases
exhibited strong and diffuse staining while others were completely negative for integrin
β4 expression (Fig. 3.3A-D). In some tumors, staining was predominantly membranous,
while others exhibited a mixture of cytoplasmic and membranous immunoreactivity (Fig.
3.4A-B). Integrin β4 staining intensity was elevated at the tumor-stromal interface in
some tumors, a phenomenon that has been previously described by others (Fig.3.4C).102
Individual infiltrating tumor cells and nests at the invasive front also tended to have
elevated integrin β4 expression compared to cells at the center of the tumor (Fig. 3.5).

Integrin β4 expression and association with clinical features
In our TMA cohort, integrin β4 expression was elevated in squamous cell
carcinomas when compared to adenocarcinomas (Fig. 3.6A; P < 0.0001); this finding
was confirmed in two external gene expression datasets (Fig. 3.6B-C; P < 0.0001).
Integrin β4 protein expression was also elevated in a subset of adenosquamous
carcinomas and poorly differentiated tumors that were evaluated in our TMA (Table 3.2).
Using data abstracted from pathology reports, integrin β4 overexpression was found to
associate with the presence of venous invasion (Fig. 3.7; P = 0.0037). To date, no data
have been published that demonstrate an association between integrin β4 expression
and patient outcome in NSCLC. In our TMA cohort, integrin β4 overexpression was
significantly associated with shorter overall survival (Fig 3.8A; hazard ratio 1.457, 95%
confidence interval 1.013 to 2.094, P = 0.0422). This relationship was also significant
when using a higher cutoff point to define integrin β4 overexpression (Fig. 3.8B; hazard
ratio 1.714, 95% confidence interval 1.171 to 2.510, P = 0.0056). Furthermore, elevated
integrin β4 gene expression in the Hou dataset was associated with reduced one year
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survival (Fig. 3.8C; P = 0.0062), and showed a trend towards reduced overall survival
(Fig. 3.8D; hazard ratio 1.674, 95% confidence interval 0.8977 to 3.120, P = 0.1051). In
the TCGA dataset, higher levels of integrin β4 gene expression were associated with
reduced overall survival (Fig. 3.8E-F; hazard ratio 1.714, 95% confidence interval 1.052
to 2.792, P = 0.0305). cBioportal was used to generate a list of genes most positively
correlated with ITGB4 in squamous cell lung cancers. ITGB4 expression was highly
correlated with expression of stem cell markers ITGA6 and CD44 (Figure 3.9A-B; P <
0.0001). Expression of EGFR was also highly correlated with ITGB4 expression (Fig.
3.9C). In addition, a network map was generated using cBioPortal. This map
demonstrates highly altered genes neighboring ITGB4 (Fig. 3.10). These genes included
various laminins, collagens, CD151, the Myc pathway, EGFR, Met, Yes and genes in the
PI3K-AKT pathway.
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Figure 3.2: Expression of the integrin β4 in benign and neoplastic lung. In the Hou
dataset, NSCLCs had greater average levels of ITGB4 mRNA than normal lung, P <
0.0001 via two tailed t-test with Welch's correction (A). In benign bronchial epithelium,
integrin β4 had moderate expression in basal cells and along the basement membrane,
with weak expression at the apical surface of ciliated columnar cells (B). However, in
invasive carcinoma, integrin β4 was overexpressed and basal polarization was lost (C,
D).
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Figure 3.3: Integrin β4 staining intensity in non-small cell lung carcinoma.
Examples of negative (A), weak (B), moderate (C), and strong (D) integrin β4 expression
in NSCLCs. Left panels show integrin β4 staining, right show H&E. Magnification = 200x,
all images.
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Figure 3.4: Localization of integrin β4 staining in NSCLC. Some cases exhibited
predominantly membranous staining (A), while others had strong membranous and
cytoplasmic expression of the integrin β4 (B). In some cases, integrin β4 was elevated
predominantly at the tumor-stroma interface (C). Magnification = 200x, all images.
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Figure 3.5: Integrin β4 expression at the invasive front. Integrin β4 expression is
elevated in infiltrating cells at the invasive front of a poorly differentiated NSCLC.

43

Table 3.2: Integrin β4 expression in NSCLC by histologic subtype.
Integrin β4 High

Integrin β4 Low

101/211 (48%)

110/211

Squamous cell carcinoma

77/99 (78%)

22/99 (22%)

Adenocarcinoma

11/81 (14%)

70/81 (86%)

Poorly differentiated

5/12 (42%)

7/12 (58%)

Adenosquamous

7/12 (58%)

5/12 (42%)

Mixed histology

1/2 (50%)

1/2 (50%)

Large cell neuroendocrine

0/2 (0%)

2/2 (100%)

Pleomorphic carcinoma

0/1 (0%)

1/1 (100%)

Giant cell carcinoma

0/1 (0%)

1/1 (100%)

Sarcomatoid carcinoma

0/1 (0%)

1/1 (100%)

Total
Histologic Type:

Other histologic types:
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Figure 3.6: Integrin β4 expression in NSCLC by histologic subtype. SCCs had a
higher proportion of cases with integrin β4 overexpression than did adenocarcinomas, as
measured using semi-quantitative IHC, P < 0.0001 via Mann-Whitney test (A). In a
TCGA NSCLC dataset, average ITGB4 mRNA expression was higher in SCCs than in
adenocarcinomas, P = 0.0001 via two-tailed t-test (B), and in the Hou dataset, average
ITGB4 mRNA expression was higher in SCCs when compared to both normal lung
tissue and adenocarcinomas, P < 0.0001 via one-way ANOVA with post hoc Tukey’s test
(C).
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Figure 3.7: Integrin β4 is elevated in tumors with venous invasion. Integrin β4
overexpression is associated with the presence of venous invasion, P = 0.0037 via
Mann-Whitney test (A). An example of a tumor from the TMA with venous invasion,
stained for integrin β4 and elastic trichrome (B). In the elastic trichrome, black staining
highlights elastic fibers of the vein wall, and tumor fills the vessel.
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Figure 3.8: Integrin β4 and survival in NSCLC. In our TMA cohort, elevated
expression of integrin β4 was associated with shorter median overall survival, P =
0.0422 (A) and P = 0.0056 (B). In the Hou cohort, average ITGB4 mRNA levels were
higher in patients that were deceased at one year (C), and there was a trend towards
reduced overall survival for patients with elevated ITGB4 mRNA expression (D). In the
TCGA cohort, elevated ITGB4 mRNA expression was associated with reduced overall
survival depending on the cutoff point used, P = 0.0305 (E and F). Survival analyses in
(A), (B), and (D) were done via log-rank (Mantel-Cox) tests.
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Figure 3.9: ITGB4 expression correlates with ITGA6, CD44, and EGFR in SCC.
By linear regression, ITGB4 mRNA expression levels were positively correlated with
ITGA6 (A), CD44 (B), and EGFR (C).
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Figure 3.10: Network map illustrating highly altered genes associated with ITGB4.
In this network map generated using cBioPortal, ITGB4 is connected to laminins
(LAMC2, LAMA1, LAMB1, LAMA2, etc), genes in the EGFR family (EGFR, ERBB3),
genes in the PI3K pathway (PIK3CA, AKT1), other integrins (ITGA6, ITGB1) and the
tetraspanin CD151.
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Discussion
In this study, I found that integrin β4 is highly expressed in lung SCC, and that its
overexpression is associated with venous invasion and reduced overall survival in
patients with NSCLC. These results are in accordance with findings in other cancers that
demonstrate

an

association

between

integrin

β4

overexpression

and

poor

prognosis.50,100,109 Previous studies have demonstrated that the integrin β4 is highly
expressed in SCC, however, this is one of the first studies to demonstrate that it has
prognostic significance. Early reports have shown that expression of the integrin α6β4
(previously described as TSP-18084) is elevated in murine Lewis lung carcinoma variants
with high metastatic potential.154,155 As mentioned previously, integrin β4 has been
shown to form a complex with and to amplify ErbB-2 signaling, and notably, ErbB-2 and
integrin α6β4 co-localization have been identified in the lung cancer cell line Calu-3.156
Multiple studies investigating integrin β4 expression in patient-derived tissues have
shown that it is expressed in NSCLC, with high levels observed in squamous cell
carcinomas.101-103 A more recent study using gene expression profiling identified
differentially expressed genes in samples of pulmonary ADC, SCC, and normal
bronchus.104

In this study, integrin β4 was found to be significantly upregulated in

SCC.104 Notably, the integrin β4 gene (ITGB4) is upregulated in the basal molecular
subtype of lung SCC as defined using unsupervised clustering of gene expression
microarray data.157
Tumor metastases are responsible for the majority of cancer related deaths.158 In
order for cancer cells to metastasize, they must acquire access to the circulation through
a process termed intravasation.159 Integrin β4 has been shown to enhance tumor cell
binding to the vascular endothelium, and can also mediate vascular permeability through
its effects on vascular endothelial growth factor (VEGF) expression.160,161 Notably,
integrin β4 mediated signaling has been shown to enhance VEGF protein expression by
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upregulating its cap-dependent translation.161 VEGF expression leads to the disruption
of endothelial junctions, thus allowing tumor cells to enter the circulation where they can
travel to distant sites, extravasate, and metastasize.160 We have shown that integrin β4
overexpression is associated with venous invasion in NSCLC, and its effects on VEGF
expression may be partially responsible for this phenomenon. In addition, integrin β4
has been shown to promote the expression of a number of pro-metastatic and proinvasive proteins including S100A4,35 which also contributes to its ability to promote
vascular invasion and tumor metastases.
In this study, expression of the integrin β4 gene was positively correlated with
expression of the cancer stem cell maker, CD44.162 CD44 is a transmembrane
glycoprotein that has been shown to facilitate many aspects of tumor progression and is
important in promoting resistance to therapy.162-164 Interestingly, integrin β4 has been
implicated in promoting stem cell like properties in breast cancer,165 and has been
identified in the cancer stem cell population in NSCLC.166 Integrin β4 gene expression
was found to positively correlate with expression of EGFR, and in the network map,
integrin β4 was connected to genes in the EGFR signaling pathway. These findings are
notable in light of evidence demonstrating a functional relationship between EGFR and
integrin β4.7,167 In particular, integrin β4 has been shown to interact with EGFR in lipid
rafts where it enhances cell growth and proliferation.40

Furthermore, our lab has

demonstrated that in pancreatic cancer, integrin α6β4 promotes autocrine EGFR
signaling (unpublished data). In the network map, integrin β4 was connected to a
number of laminins (LAMA3, LAMC2, LAMB4), which is consistent with the fact that
integrin β4 binds laminins in the extracellular matrix. Also notable was the connection
between integrin β4 and COL17A1, (Collagen, Type XVII, Alpha 1), as this gene
encodes the BP180 protein that is necessary for hemidesmosome assembly. Finally,
expression of integrin β4 gene was correlated with that of its binding partner, integrin α6.
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In summary, I have demonstrated that integrin β4 is elevated in NSCLCs
compared to normal lung tissue, and that it is overexpressed in lung SCC. Furthermore,
a positive association was demonstrated between the presence of venous invasion and
integrin β4 overexpression. Integrin β4 overexpression was associated with reduced
overall survival in patients included in the TMA, as well as in external cohorts. While
difficult to quantify on tissue microarray sections, integrin β4 expression was noted to be
elevated at the invasive front of numerous tumors.

52

CHAPTER 4: ,17(*5,1α6β4 ,6'2:15(*8/$7('%<087$17,'+$1'
$662&,$7(6:,7+$:256(&/,1,&$/287&20(,1*/,20$6
Gliomas account for 30% of all primary tumors of the central nervous system (CNS)
and represent about 80% of malignant CNS tumors.168 In adults, this class of tumors
tends to have a poor prognosis, with 5-year survival rates for high-grade gliomas ranging
from 4%-52%.168 Glioblastoma multiforme (GBM) accounts for over 50% of gliomas and
carries an extremely poor prognosis, with a median survival of around only 14 months
even when treating with temozolomide and radiation therapy.169 A key reason for this
dismal prognosis is the diffusely infiltrative nature of these tumors, which renders
complete surgical excision impossible.
Tumors of the central nervous system can be classified into four categories using
criteria developed by the World Health Organization (WHO). These categories include
tumors that range from those with low proliferative potential (Grade I) to tumors that are
cytologically malignant and display increased mitotic activity and areas of necrosis
(Grade IV).170 This histologic grading system provides a mechanism that can assist with
the prediction of biologic behavior and response to therapy.
Mutations in isocitrate dehydrogenases types 1 and 2 (IDH1/2) have been
identified in a number of human malignancies, including gliomas, chondroid tumors, and
acute myeloid leukemia (AML).171-174 These mutations are present in the majority of
WHO grade II and III gliomas, and are also characteristic of secondary GBMs.174-177
Both enzymes normally oxidize isocitrate to alpha-ketoglutarate, but point mutations at
R132 in IDH1 or R172 in IDH2 produce neoenzymatic activity, reducing alphaketoglutarate

to

D-2-hydroxyglutarate

(2-HG).178,179

2-HG

may

contribute

to

gliomagenesis by promoting histone and DNA hypermethylation and suppressing cellular
differentiation.180 Although IDH1/2 mutations have been shown to contribute to
gliomagenesis, they do not appear to be sufficient for tumor induction.181,182 It is likely
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that IDH1/2 mutations are early events in gliomagenesis that, when coupled with either
TP53 or 1p/19q co-deletion, can lead to tumor development.181,183 In particular, these
mutations are powerful favorable prognostic markers, though the reasons for this have
not been fully elucidated.181
Expression of the integrin β4 subunit has not been extensively studied in gliomas,
and it is not known whether integrin β4 has clinical or prognostic significance in these
tumors. Furthermore, the effect of IDH1 mutations on the expression of cellular adhesion
molecules such as the integrin β4 is unknown. We therefore investigated integrin β4
expression in a cohort of grade II-IV gliomas with and without IDH1 mutations, integrated
results with outcome, and evaluated the effect of R132H IDH1 overexpression on
integrin α6β4 levels in human glioma cells. Here, we report that integrin α6β4 is
associated with progression and reduced overall survival in diffuse gliomas and is
inversely correlated with mutant IDH1 status, potentially identifying a factor contributing
to the more favorable prognosis associated with mutant IDH1.

Materials and Methods:
*OLRPDWLVVXHPLFURDUUD\
Formalin-fixed, paraffin-embedded (FFPE) glioma tissues were retrieved from the
pathology archives at the University of Kentucky. Deidentified tissue microarrays (TMAs)
were constructed from the gliomas as previously described.184 A total of 104 cases
comprised the TMAs, including 9 nonneoplastic controls (cortical dysplasia), 9 grade II
astrocytomas, 11 grade III astrocytomas, 12 anaplastic oligodendrogliomas, 16 grade II
oligodendrogliomas, and 47 grade IV GBMs. Treatment and outcomes were obtained via
the Kentucky Cancer Registry. Institutional Review Board approval was obtained prior to
collecting the archival tissues for TMA construction and patient retrieval data.
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Immunohistochemistry VFRULQJDQGDQDO\VLV
Immunohistochemistry for the integrin β4 subunit was performed as described in
Chapter 2. Specifically, the primary antibody was used at 1:100 and the secondary
antibody was used at 1:500. Integrin β4 expression was scored using a semiquantitative
scale as follows: negative (0), minimal staining (1), weakly positive (2), moderately
positive (3), strongly and diffusely positive (4). Endothelial cells were used as internal
positive controls while non-neoplastic tissue cores served as negative controls. Scoring
was done while blinded to WHO grade and IDH1 mutation status. Results from all three
tissue cores were averaged together to produce a final score for each tumor.
R132H IDH1 immunohistochemistry of TMAs was performed as previously
described.184 Of note, 5 TMA cases were immunonegative for R132H IDH1 but were still
suspected of having a less common IDH1 or IDH2 mutation based on mutationassociated variables like WHO grade and younger patient age. Of those 5, a single
anaplastic astrocytoma turned out to have R132S IDH1 via pyrosequencing.
Pyrosequencing was performed in the Molecular Pathology Department at the University
of Kentucky according to a clinically validated protocol.
Immunoblotting
LN18-GFP, LN18-GFP WT IDH1 and LN18-GFP IDH1 mutant cell lines were
generated as previously described.184 Cells were harvested in RIPA buffer (150 mM
NaCl, 0.5 mM EGTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM
Tris-HCl pH 7.4, 15 μg/ml protease inhibitor cocktail, 1 mM PMSF). Total cell lysates (80
μg) were subjected to 8% SDS-PAGE, transferred and immunoblotted with mouse antihuman integrin β4 antibody (clone 7/CD104; BD Bioscience, San Jose, CA). β-actin was
used as the loading control. Immunoblotting was performed by Min Chen, MD, PhD.
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Bioinformatics analysis of external cohorts
To validate TMA data with external cohorts, the relationship of integrin β4 to tumor
type and GBM patient survival was done using the Oncomine microarray database
(Oncomine, Compendia Bioscience, Ann Arbor, MI http://www.oncomine.org). Specific
correlations between ITGB4 mRNA and IDH1 status, or ITGB4 mRNA and other
mRNAs, were done via direct query of The Cancer Genome Atlas (TCGA Research
Network, http://cancergenome.nih.gov/). Additional survival data in a separate cohort of
GBMs was obtained via the National Cancer Institute REpository for Molecular BRAin
Neoplasia DaTa (REMBRANDT, https://caintegrator.nci.nih.gov/rembrandt/).

Results
To

determine

the

range

of

integrin

α6β4

expression

in

gliomas,

immunohistochemistry for the β4 subunit was performed on a set of glioma TMA blocks
from 104 cases (see Materials and Methods). Integrin β4 expression was uniformly weak
in nonneoplastic control tissues, but showed a greater range of staining intensities in
grades II-III gliomas (Figs. 4.1 and 4.2A). However, the overall mean intensity was
significantly greater only in grade IV GBMs (Fig. 4.2A; P < 0.0001). After adjusting for
WHO grade, no significant difference in β4 expression was seen between astrocytic and
oligodendroglial tumors (Fig. 4.3A). External cohorts confirmed this association, showing
elevated ITGB4 mRNA in GBMs compared to nonneoplastic brain (Figs. 4.2B and 4.3B).
Patient-derived nonneoplastic neural progenitor cells also showed significantly lower
ITGB4 mRNA in vitro compared to primary patient-derived GBM cells and some other
commonly-used GBM cell lines (Fig. 4.3C).
In carcinomas, integrin β4 is known to promote more invasive and aggressive
behaviors50,53,72,86,99,105,110 and has been shown to upregulate S100A4,172 a gene
encoding for a pro-metastatic protein that is involved in the epithelial to mesenchymal
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transition.185 Gene expression profiling has identified multiple molecular subtypes of
GBM, including a mesenchymal phenotype.186 In the TCGA set of GBMs, increasing
levels of ITGB4 mRNA correlate with increasing levels of CHI3L1 and S100A4 (P <
0.0001), both of which are robust mesenchymal markers (Fig. 4.4A-B), and average
ITGB4 mRNA levels were the highest in the mesenchymal sub-type of GBMs (Fig.
4.4C).
Mutant IDH1 has been shown to be a strong favorable prognostic factor in diffusely
infiltrative gliomas,181 and high integrin β4 expression can contribute to cancer
invasiveness and aggression.50,53,72,86,99,105,110 Interestingly, a strong inverse relationship
between IDH1 mutations and integrin β4 expression was observed in our TMA cohort (P
< 0.0001) (Figs. 4.5 and 4.6A-B). Likewise, TCGA GBMs that had IDH1 mutations
showed lower ITGB4 mRNA levels than IDH1 wild-type tumors (P = 0.005) (Fig. 4.6C).
In the TCGA, IDH1-mutant GBMs also showed a slight increase in ITGB4 promoter
methylation (P = 0.0008) (Fig. 4.6D). To test whether IDH1 mutations can drive the
reduction in integrin β4 expression, we analyzed LN18 GBM cells overexpressing either
wild-type IDH1 or R132H IDH1 mutant. We found that R132H IDH1 overexpression
downregulated integrin β4 protein levels compared to either the control vector
transfected or wild-type IDH1 expressing cells (P < 0.0001) (Figs. 4.6E-F). These data
suggest that mutant IDH may suppress integrin β4.
To date, no data on integrin β4 and outcome in gliomas has been published. In our
TMA cohort, high integrin β4 expression significantly associated with shorter overall
survival (OS) in all grade II-IV gliomas (median survival not reached for integrin β4 IHC
score < 1; 63.5 months for 1-1.9; 18.1 months for 2+, P = 0.0005) (Fig. 4.7A), as well as
when considering only high-grade (III-IV) gliomas (30.7 months for integrin β4 IHC score
<2; 17.8 months for 2+, P = 0.02) (Fig. 4.7B). When focusing only on GBMs, however,
no significant difference was seen (10.9 months for integrin β4 IHC score <2; 9.3 months
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for 2+, P = 0.97). However, in both the TCGA and NCI Rembrandt GBM datasets,
increasing levels of ITGB4 mRNA correlated with worse OS (Figs. 4.7C-D) This
indicates that integrin β4 may have an effect on outcome in GBMs as has been seen in
other cancers, but that larger cohorts are needed to demonstrate this. Moreover, in our
TMA cohort, integrin β4 was not an independent prognostic factor when including
variables like WHO grade and IDH1 status (Table 4.1).
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Figure 4.1: Integrin β4 expression in gliomas. Average integrin β4 levels are
significantly increased in grade IV GBMs compared to nonneoplastic brain tissues and
grade II and III gliomas. The inset in the grade IV integrin panel highlights membranous
staining of integrin β4 in GBM cells (arrowheads). Magnification = 400x for all images.
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Figure 4.2: Integrin β4 expression is higher in grade IV GBMs than lower grades of
gliomas. (A) GBMs had a higher level of integrin β4 expression than lower grade tumors
and nonneoplastic brain tissue, as measured by semiquantitative immunohistochemistry.
No significant differences were seen between grades II and III gliomas, or between II-III
gliomas and nonneoplastic tissue. Overall P < 0.0001 via one-way ANOVA, *P < .0001
between grade IV GBMs and each other group via post-hoc Tukey’s test. (B) Likewise,
TCGA GBMs showed greater average levels of ITGB4 mRNA than nonneoplastic brain.
P = 0.01 via two-tailed t-test.
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Figure 4.3: Integrin β4 expression by glioma histotype and cell lines. (A) There was
no significant difference between mean integrin β4 IHC scores among astrocytomas
(astro) or oligodendrogliomas (oligo), either at the grade II level or grade III level. P =
0.51 via one-way ANOVA. (B) In the Bredel 2 glioma cohort obtained through Oncomine
(see Methods), there was a strong trend toward higher ITGB4 mRNA in GBMs versus
nonneoplastic control brain and grades II-III gliomas (P = 0.05 via one-way ANOVA). (C)
In the Lee data obtained through Oncomine (see Methods), nonneoplastic human neural
progenitor cells (NPCs) had lower ITGB4 mRNA compared to primary cultures of
patient-derived GBMs and three GBM cell lines: U373 MG, U251, and U387. Overall P <
0.0001 via one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001 via post-hoc Tukey’s
test. For the sake of simplicity, other statistically significant differences that were found
(e.g. between U373 MG and U188 MG) are not shown. Data in this figure analyzed by
Craig Horbinski, MD, PhD.
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Figure 4.4: Integrin β4 expression correlates with mesenchymal markers in TCGA
GBM dataset. By linear regression, ITGB4 mRNA positively correlates with
mesenchymal markers CHI3L1 (A) and S100A4 (B) in TCGA GBMs. N = 424. (C) By
GBM expression subtype, average ITGB4 mRNA levels were the highest in
mesenchymal GBMs, with proneural tumors showing the lowest ITGB4 levels. Overall P
< 0.0001, *P < 0.05, **P < 0.01, ***P < 0.001. N = 434. . Data in this figure analyzed by
Craig Horbinski, MD, PhD.
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Figure 4.5: Integrin β4 immunoreactivity in IDH1-mutant versus wild type gliomas.
Compared to a grade IV GBM that is wild-type for IDH1 (left panels), a GBM with R132H
IDH1 has less intense integrin β4 staining (right panels). Magnification = 400x for all
images.
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Figure 4.6: Integrin β4 expression is lower in IDH1-mutant gliomas. Tumors with
mutant IDH1 showed significantly less integrin β4 expression via immunohistochemistry,
either by pooling all grade II-III gliomas together (A) or by focusing only on high-grade (III
& IV) gliomas (B). Likewise, IDH1-mutant GBMs from the TCGA had lower levels of
ITGB4 mRNA compared to wild-type GBMs (C) and tended to have more methylation of
cg23913400, a CpG island in the ITGB4 promoter (D). Overexpression of R132H IDH1
markedly downregulated integrin β4 in LN18 glioma cells (E), densitometric data from 5
independent blots were combined and quantified in (F). Statistical analyses in (A-D)
were done via two-tailed t-tests; (F) was done via one-way ANOVA. *P < 0.05 versus
vector, **P < 0.001 versus vector and wtIDH1 as determined by post hoc Tukey’s test.
Data in E and F generated by Min Chen, MD, PhD.
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Figure 4.7: Integrin β4 and survival in gliomas. When pooling all gliomas together
(A), increased expression of integrin β4 (categorized by the semiquantitative data as
shown in Figures 1 and 2A) correlated with shorter median OS. *P = 0.004 versus 1-1.9
and *P = 0.0003 versus < 1. There was no significant difference between < 1 and 1-1.9
(P = 0.14). Even when focusing on just high-grade (III & IV) gliomas (B), expression
levels of 2 or more still correlated with worse OS, P = 0.02. (C) In TCGA GBMs,
increasing ITGB4 mRNA levels significantly correlated with decreased proportion of
patients surviving 5 years. Overall P = 0.002 via Kruskal-Wallis test; post-hoc values
were derived via Dunn’s multiple comparison test. (D) In the NCI Rembrandt dataset,
GBMs with upregulation of ITGB4 mRNA (as defined by > 3-fold increased mRNA levels
compared to nonneoplastic control tissue) had a 30% shorter median survival compared
to GBMs with less than threefold increase in ITGB4 mRNA (13.2 versus 17.1 months).
Survival analyses in (A), (B), and (D) were done via log-rank (Mantel-Cox) tests.
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Variable

Relative risk

95% CI

P

integrin β4 moderate to high

1.3

0.61—2.6

0.55

grade III-IV vs II

21.3

4.4—104.6

0.0002

age < 45 years

0.81

0.41—1.6

0.55

astrocytic morphology

1.3

0.48—3.4

0.62

IDH1 status

0.21

0.069—0.63

0.0052

adjuvant radiation

0.42

0.19—0.91

0.029

adjuvant TMZ

0.32

0.16—0.67

0.0023

Table 4.1: Multivariate survival analysis of gliomas. Via Cox proportional hazards
survival regression (N = 88), significant independent prognostic factors included high
WHO grade, IDH1 mutations, adjuvant radiation, and adjuvant temozolomide (TMZ), but
not integrin β4 expression (2+ versus < 2 as described in Figures 1 and 2). All tumors
underwent extensive resection, not just biopsy. Multivariate analysis performed by Craig
Horbinski, MD, PhD.
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Discussion
The results of this study demonstrate that integrin β4 is highly expressed in GBMs
compared to lower grade gliomas and non-neoplastic tissue. We found that high integrin
β4 expression is an adverse prognostic marker, which is consistent with work done in
other cancers showing that integrin α6β4 overexpression imparts more aggressive,
invasive behavior.50,53,72,86,99,105,110 We also found that integrin β4 was significantly lower
in tumors with IDH1 mutations, which was confirmed in external gene expression
databases, and that overexpressing R132H IDH1 sharply suppresses integrin β4
expression in glioma cells. This may help explain why IDH1/2-mutant gliomas tend to be
less aggressive than their wild-type counterparts.187,188
To date, very few papers have been published on the subject of integrin α6β4 in
gliomas. Prior work has shown that integrin β4 expression in gliomas is variable, though
these studies examined smaller numbers of patient-derived glioma tissues. Previtali et
al.126 found that the integrin β4 expression is present in reactive astrocytes, and that
expression is elevated in astrocytomas. A larger study investigated expression of the β4
subunit in a series of astrocytomas and oligodendrogliomas, and found that β4
expression was slightly higher in oligodendrogliomas.128 Previtali et al189 found that the
α6β4 integrin was diffusely expressed in both neoplastic and reactive astrocytes in an
animal model of ethylnitrosourea (ENU) induced glioblastoma. Interestingly, they
describe that β4 staining was identified early in tumor development, and that staining
was more intense within the neoplastic cells of proliferative centers.189

Integrin β4

expression has been identified in multiple astrocytoma cell lines (SF-767, NCE G-22 and
NCE G-112) by RT-PCR,190 and was identified in the oligodendroglial cell line HS-683.128
More recently, a study was published describing the interaction between the β4 integrin
and netrin-4 (NTN4) in glioblastoma progression.191 The current study is the first to
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show that integrin α6β4 is higher in GBMs than lower-grade gliomas, that it is an
adverse prognostic marker, and that mutant IDH1 suppresses its expression.
Within GBMs, integrin β4 had no prognostic significance in the TMA cohort,
although it did in external GBM databases (Figure 5). This is likely due to the fact that
the external cohorts were larger. Moreover, integrin β4 was not an independent
prognostic marker on multivariate analysis (Table 1), which may be due to the fact that
integrin β4 is so tightly correlated with IDH1 mutation status and tumor grade (Figures 24). Thus, it is very unlikely that lower integrin β4 expression is the sole reason why
mutant IDH1 is a positive biomarker, but rather that it contributes to the overall favorable
prognosis in such tumors. For example, mutant IDH1 also leads to MGMT promoter
hypermethylation, thus reducing the ability of the tumor to repair DNA damage done by
alkylating chemotherapeutic agents. It is therefore not surprising that a mutation that
triggers global hypermethylation would accidently make a few changes that are
somewhat deleterious to the tumor.181 Epigenetic regulation of integrin β4 through
promoter hypermethylation and histone modification has been previously described.192
Whether hypermethylation is the mechanism by which mutant IDH1 suppresses integrin
β4 mRNA and protein expression is the subject of ongoing research.
The role of integrins in glioma development and progression is a growing
component of neurooncology research. For example, integrin α6 is a marker for GBM
stem cells, and its interaction with laminin α2 in the extracellular matrix is an important
mediator of stem cell properties like self-renewal and tumor formation.193,194 Integrin ß8 is
also expressed in gliomas, positively correlates with overexpression of EGFR and
PDGFRA, and may promote FAK and ERK activity in regions rich in extracellular
matrix.195 The αvβ3 and αvβ5 integrins have been implicated in tumor-induced
angiogenesis,196 which is a common feature of GBMs.197 The αvβ3 and αvβ5 integrins
increase with increasing histologic grade in gliomas, and tumor cells at the periphery of
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high-grade gliomas have higher αvβ3 expression.198 Attempts to target αvβ3 and αvβ5 in
GBM led to multiple clinical trials with cilengitide, a small molecule inhibitor of the αvβ3,
αvβ5 and α5β1 integrins.199 While a phase II clinical trial (NABTT 0306) demonstrated a
modest improvement in median survival for patients treated with cilengitide, further
studies in patients with newly diagnosed GBM have not been successful.169,200
In summary, we have demonstrated that expression of the β4 integrin is decreased
in tumors with mutations in IDH1, which we confirmed using a glioma tissue microarray,
gene expression databases, and overexpression of R132H IDH1 in vitro. This study is
the first to demonstrate that mutant IDH1 can decrease the expression of a cell adhesion
molecule. Further work is needed to clarify the mechanism(s) by which mutant IDH1
alters the expression of cellular adhesion molecules, and to examine the role of integrin
α6β4 in gliomagenesis and invasion. Gaining a deeper understanding of why mutant
IDH1 gliomas are less aggressive than their wild-type counterparts will not only help
develop ways of targeting IDH1-mutant gliomas, but also of making wild-type tumors
behave more like mutant tumors.
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CHAPTER FIVE: INTEGRIN α6β4 EXPRESSION IN NORMAL AND NEOPLASTIC
BREAST
Breast cancer is the most common IRUPRIcancer diagnosed among women in the
United States, and is also a leading cause of cancer related death among women in this
country.132 Breast cancer is responsible for over 40,000 deaths annually, and incidence
continues to rise.132 It is now estimated that 1 in 8 women will be diagnosed with breast
cancer during their lifetime.132 While advances in clinical care have resulted in improved
survival for many women with breast cancer, there are still subtypes that carry a poor
prognosis and remain difficult to treat effectively. Importantly, breast cancer does not
represent one disease, but instead represents a number of different disease processes,
all with unique morphologies and molecular phenotypes.

&OLQLFDODQGPROHFXODUVXEW\SHVRIEUHDVWFDQFHU
From a clinical perspective, breast cancer can be divided into three main
categories: hormone receptor positive, HER2 positive, and triple negative. These clinical
subtypes of breast cancer are defined by expression of the estrogen receptor,
progesterone receptor, and HER2 (ERBB2). Assessment of these three markers is
routine in clinical practice. While expression of ER and PR are assessed using
immunohistochemistry, HER2 expression can be assessed using immunohistochemistry,
fluorescence in situ hybridization (FISH), or chromogenic in situ hybridization (CISH).
Hormone receptor positive tumors generally express the estrogen receptor (ER) and
have variable expression of the progesterone receptor (PR). Patients whose tumors are
hormone receptor positive are generally candidates for therapy with hormone receptor
antagonists, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and
drugs that suppress ovarian function. Patients with amplification or overexpression of
HER2 can now be treated with a wide array of anti-HER2 therapies including monoclonal
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antibodies such as trastuzumab and tyrosine kinase inhibitors such as Lapatinib. While
these advances have significantly improved the survival of patients with breast cancer,
triple negative tumors lack expression of ER, PR, and HER2, and so are not amenable
to treatment with the therapies described above. Patients with TNBC tend to have
reduced survival when compared to patients with hormone receptor positive or HER2
amplified disease.201,202
The clinical classification of breast cancer based on expression of ER, PR, and
HER2 helps to inform and streamline clinical decision making, however, it does not
reflect the true heterogeneity of this disease. The WHO histologic classification of breast
tumors recognizes at least 37 different entities, not including primary mesenchymal and
lymphoid neoplasms of the breast.203 The epithelial subtypes of breast cancer range
from commonly encountered tumors such as invasive ductal, lobular, and tubular
carcinomas to rare entities including adenoid cystic carcinoma, secretory carcinoma, and
glycogen-rich clear cell carcinoma. While pathologists have long recognized these
diverse histologic subtypes, recent studies using molecular profiling have uncovered
specific subtypes that are based on differences in gene expression, mutation profile,
copy number alterations, and epigenetic modifications. One of the more widely accepted
classification schemes divides breast cancer into four main molecular subytpes: Luminal
A, Luminal B, HER2 and basal-like.70,204,205
Luminal A breast cancers are characterized by elevated mRNA expression of
genes such as ESR1, GATA3, FOXA1, XBP1, and by mutations in PIK3CA, GATA3 and
FOXA1.70 Luminal A tumors tend to express both ER and PR, and so are amenable to
treatment with estrogen receptor modulating agents. These tumors have the best
prognosis out of the molecular subtypes. Luminal B tumors are characterized by a higher
proliferation index than Luminal A tumors, and by mutations in PIK3CA, GATA3, and
TP53.70 The third molecular subtype is the HER2 enriched; clinically, these tumors tend
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to have amplification and/or overexpression of HER2. Mutations in PIK3CA and TP53
are common in HER2 enriched tumors. The final molecular subtype is the basal-like.
Basal-like breast cancer tends to be triple negative, though the two categories are not
mutually exclusive. Many, but not all, basal-like tumors are triple negative, though there
are some exceptions. The basal-like subtype is marked by a high frequency of TP53
mutations, and loss of TP53 function is present in the vast majority of basal-like breast
cancers.70 PIK3CA amplification and deletion of the tumor suppressors RB1 and PTEN
are also characteristic of basal-like breast cancers. These tumors tend to express basal
cytokeratins such as CK5 and CK6, and also have elevated expression of genes
associated with proliferation.70 Correspondingly, these tumors tend to be aggressive and
highly proliferative, leading them to have the poorest prognosis of all breast cancer
subtypes. Basal-like breast cancer is also common in African-American women and in
young women, which partially explains the poor prognosis associated with these patient
populations.
Ductal carcinoma in situ (DCIS) is a pre-invasive neoplasm of the breast that
accounts for up to 20% of newly diagnosed breast cancers.206 This neoplastic change
takes place in the ductal epithelium, where a proliferation of cells fills and expands the
ductal system. In order for a lesion to be classified as DCIS, the neoplastic cells must
remain confined to the duct, without invasion through the basement membrane. Once
neoplastic cells escape from the confines of the basement membrane and invade into
the stroma, the lesion is termed invasive breast cancer. While pure DCIS has a better
prognosis when compared to invasive breast cancer, it is a marker of increased risk for
the development of subsequent invasive carcinoma, and when diagnosed on core
needle biopsy, DCIS may be associated with the presence of an underlying invasive
breast cancer. In particular, high-grade DCIS is associated with a worse clinical outcome
and may be linked to the development of high-grade invasive breast cancer.207,208 It has
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been shown that DCIS can be categorized into molecular subtypes similar to those
identified in invasive breast carcinoma,209 and while low-grade DCIS is often positive for
the hormone receptors estrogen and progesterone, high-grade DCIS is commonly
hormone-receptor negative.206 DCIS has a variety of morphologic subtypes, many of
which have distinct molecular profiles and clinical outcomes.209 Included among these
subtypes are solid, cribriform, papillary, micropapillary, basal-like, apocrine and comedotype DCIS. A variety of clinical classification systems have been developed for DCIS,
though consensus guidelines focus on the evaluation of nuclear grade.210 This system
divides DCIS into low grade (grade 1), intermediate grade (grade 2), and high-grade
(grade 3) based on features such as nuclear atypia and nuclear size.210 This grading
scheme provides prognostic information, as high-grade DCIS is associated with an
increased risk for the later development of invasive breast cancer.

Materials and Methods
Breast Translational Group (BTG) TMA:
Institutional Review Board Approval (13-0608-P2H) was obtained prior to
initiating the project. Surgical resections for breast cancer performed at the University of
Kentucky from January 1, 2000 to December 31, 2012 were identified using natural
language searches in CoPath (Cerner Corporation, Kansas City, MO). A total of 343
invasive breast cancers were selected for inclusion, including 165 TNBCs, 74 HER2
positive tumors, and 104 hormone receptor positive tumors. Original hematoxylin and
eosin (H&E) stained slides were reviewed and appropriate tumor blocks were selected
from each case. Fresh H&E stained sections were then cut from each selected tumor
block. These fresh sections were then reviewed and tumor areas were selected for
inclusion in the TMA. Pathologic features, treatment and outcome data were collected
by the Cancer Research Informatics Shared Resource Facility and the Kentucky Cancer
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Registry. Tissue core placement was randomized by the Biostatistics and Bioinformatics
Shared Resource Facility. Three 2 mm diameter tissue cores were obtained from each
tumor specimen, which were transferred to recipient paraffin blocks using a TMArrayer
(Pathology Devices, Westminster, MD). The completed TMAs contained 1029 tissue
cores spread over 15 blocks. TMA sections used for integrin β4 immunohistochemistry
had interpretable tissue cores in 336/343 cases.
DCIS and Benign Breast Tissue
Institutional Review Board Approval (14-0236-P6H) was obtained prior to
initiating the project. In order to identify cases of normal breast and DCIS, CoPath
(Cerner Corporation, Kansas City, MO) was used to conduct natural language searches.
Individual cases were then reviewed and appropriate cases were selected for inclusion.
Benign breast tissue was obtained from leftover reduction mammoplasty cases, and
patients were excluded from the benign category if they had a history of atypia, in situ
disease, or invasive carcinoma. A total of 78 tissue blocks were identified, including 20
benign breast samples, 16 cases of low-grade DCIS, 18 cases of intermediate-grade
DCIS, and 24 cases of high-grade DCIS.
India Breast TMA
Breast cancers obtained from patients in India were used by the Markey
Biospecimen and Tissue Procurement Shared Resource Facility to construct tissue
microarrays by the method describe above. A total of 56 invasive breast cancers
comprised the Indian Breast TMA.
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Immunohistochemistry and TMA Scoring
For BTG TMA sections, immunohistochemistry for the integrin β4 was performed
according to the protocol described in Chapter 2. Specifically, the primary antibody was
used at 1:200 and the secondary antibody was used at 1:500. Due to differences in
tissue processing between this cohort and the India breast cancer cohort, sections from
the India TMA were stained for the integrin β4 subunit using the protocol described in
Chapter 2, but at a primary antibody concentration of 1:100 and a secondary antibody
concentration of 1:500. Immunohistochemical staining for ER, PR, and HER2 was
performed using the antibodies and protocols listed in Table 5.1 (Dako Corporation,
Carpinteria, CA, USA). Integrin β4 expression was scored using a semiquantitative scale
as follows: negative (0), minimal staining (1), weakly positive (2), moderately positive (3),
strongly and diffusely positive (4). Scoring for ER, PR, and HER2 was performed
according to guidelines published jointly by the College of American Pathologists (CAP)
and the American Society for Clinical Oncology (ASCO).211,212 Results from each of the
three tissue cores were averaged to produce a final score for each tumor. Scoring was
performed by while blinded to clinical and pathologic data.
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Table 5.1: Antibodies used for ER, PR, and HER2 immunostaining.
Marker
Product ID
AR Solution

ER
IR08461-5
EnVision
FLEX Target
Retrieval Solution,
High pH
AR Time
20 minutes
AR Temperature
97°
1° Antibody Conc. Pre-diluted
1° Incubation Time 25 minutes
2° Antibody
Anti-rabbit
(Envision+ kit)
Detection
Envision+
DAB Time
10 minutes

PR
IR06861-5
EnVision
FLEX Target
Retrieval Solution,
High pH
20 minutes
97°
Pre-diluted
25 minutes
Anti-mouse
(Envision+ kit)
Envision+
10 minutes

All reagents are from Dako Corporation.
AR = Antigen retrieval.
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HER2
A048529-1
No AR per
manufacturer’s
specifications
N/A
N/A
1:100
20 minutes
Anti-rabbit
(Envision+ kit)
Envision+
10 minutes

Results
Integrin β4 expression in benign breast and DCIS
In benign breast tissue, integrin β4 was strongly expressed in myoepithelial cells,
while staining in luminal epithelial cells was absent (Fig. 5.1A). This pattern was
preserved in fibrocystic change and apocrine metaplasia (Fig. 5.1B). In usual ductal
hyperplasia and columnar cell change without atypia, integrin β4 expression was limited
to myoepithelial cells (data not shown). Microglandular adenosis is a benign proliferation
that is believed to be a non-obligate precursor to invasive TNBC.213 Interestingly, integrin
β4 expression was elevated in the single example of microglandular adenosis studied
(Fig. 5.1B). Benign stroma, fibroblasts, adipose, and infiltrating lymphocytes were all
negative for expression of the integrin β4 (Fig. 5.1). In benign breast tissue, endothelial
cells and peripheral nerves had weak to moderate expression as has been previously
described (Fig. 5.2).72
Expression of the integrin β4 in DCIS was variable. In some cases, integrin β4
expression was present only in the residual myoepithelial cells lining DCIS (Fig. 5.3),
whereas in other cases, integrin β4 expression was present in both neoplastic and
myoepithelial cells. Within DCIS, integrin β4 expression was heterogeneous. There was
a tendency for neoplastic cells in the outer layers of DCIS (adjacent to myoepithelial cell)
to have elevated integrin β4 expression (Fig. 5.3).

Integrin β4 in invasive breast cancer
Integrin β4 expression in invasive breast cancer was also variable (Figs. 5.4 and
5.6B-C). In some cases, infiltrating tumor cells exhibited strong and diffuse expression of
the integrin β4, while others were completely negative for integrin β4 expression (Fig.
5.4). In the India TMA cohort, we found that integrin β4 expression was elevated in
TNBCs and HER2 positive breast cancers (Fig. 5.4). Although the number of HER2
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positive tumors in this cohort was relatively small (N =14), integrin β4 overexpression
was identified in the majority of these HER2 positive tumors (Fig. 5.5). In addition,
integrin β4 overexpression was associated with high tumor grade in this cohort (Table
5.2). An association was not identified between tumor size or the presence of lymph
node metastasis in the India TMA cohort (Table 5.2).
In the BTG TMA cohort, low-grade breast cancers such as tubular and cribriform
carcinoma had low to absent expression of the integrin β4 (Fig. 5.6B). In the few tumors
examined with residual benign ductal epithelium, integrin β4 was still present in
myoepithelial cells surrounding the ducts (Figs. 5.6B and 5.7). In high-grade breast
cancers, integrin β4 was expressed strongly and diffusely throughout infiltrating tumors
cells (Fig. 5.6C). Integrin β4 expression was elevated in TNBCs and HER2 positive
tumors when compared to hormone receptor positive breast cancers, with the highest
levels of integrin β4 expression observed in TNBCs (Fig. 5.8A). Furthermore, integrin β4
expression was associated with high tumor grade in the BTG TMA cohort (Fig. 5.8B).
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Figure 5.1: Integrin β4 expression in benign breast. Integrin β4 expression in benign
breast with fibrocystic change (A). Integrin β4 is absent in cells with apocrine metaplasia
(center lesion), however, expression is elevated in adjacent benign microglandular
adenosis (B).

79

Figure 5.2: Integrin β4 expression in endothelial cells and peripheral nerve. In a
medium sized vessel, integrin β4 is expressed in endothelial cells lining the lumen (A).
and is also expressed in peripheral nerves (B).
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Figure
5.3:
Integrin
β4
expression in DCIS. Low grade
DCIS
with
integrin
β4
expression in myoepithelial cells
surrounding neoplastic duct (A).
Intermediate grade DCIS with
elevated integrin β4 expression
in myoepithelial and neoplastic
cells (B). All images = 200x.
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Figure 5.4: Integrin β4 expression patterns in clinical breast cancer subtypes. In
the India TMA cohort, integrin β4 levels were significantly higher in triple negative and
HER2 positive tumors. Paraffin-embedded breast cancer tissues were stained with
antibodies to the integrin β4 subunit, ER, PR, and HER2. Representative images of triple
negative, hormone receptor positive, and HER2 overexpressing tumors are shown.
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Figure 5.5: Integrin β4 expression is elevated in HER2 positive tumors. Integrin β4
expression was elevated in a subset of HER2 positive tumors in the India TMA. Panels
A-D each show an example of a tumor stained for ER, PR, HER2 and integrin β4.
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Table 5.2: Integrin β4 expression and clinicopathologic features in breast cancer.

Average tumor size
Nodal disease
Positive
Negative
Tumor Grade
II
III
HER2 status
Positive
Negative
Subtype
Triple negative
Hormone receptor +

β4 High

β4 Low

(n= 23)

(n=31)

3.99 cm
P = 0.8617

3.91 cm

17/40 (42.5%)
6/14 (43%)
P = 1.000

23/40 (57.5%)
8/14 (57%)

2/15 (13%)
21/39 (54%)
P = 0.0125

13/15 (87%)
18/39 (46%)

10/14 (71%)
13/39 (33%)
P = 0.0259

4/14 (29%)
26/39 (66%)

7/10 (70%)
8/34 (24%)
P = 0.0187

3/10 (30%)
26/34 (76%)
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Figure 5.6: Examples of integrin β4 staining in the BTG TMA.
The top panel demonstrates integrin β4 expression in benign ductal epithelium. The
myoepithelial cells display strong staining for the integrin β4, whereas luminal epithelial
cells are negative for integrin β4 expression (A). In this low grade invasive breast cancer,
integrin β4 remains positive in the myoepithelial cells of benign ducts, but is absent in
adjacent invasive carcinoma (B). In this high-grade invasive breast cancer, integrin β4 is
strongly and diffusely expressed (C).
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Figure 5.7: Example of integrin β4 relocalization. In the benign ducts and lobules
(right) integrin β4 is highly expressed in myoepithelial cells, and at the basal aspect of
luminal cells. In the invasive carcinoma (left), integrin β4 expression appears reduced,
however, this relocalization of integrin β4 may be clinically significant due to a change in
β4 signaling after release from hemidesmosomes.
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Figure 5.8: Elevated integrin β4 expression is associated with clinical subtype and
tumor grade. In the BTG TMA, integrin β4 levels were higher in triple negative and
HER2+ breast cancers when compared to hormone receptor positive (HR+) breast
cancers, P < 0.0001 via Kruskal-Wallis test with Dunn's Multiple Comparison Test (A).
Average integrin β4 levels were also elevated in high-grade breast cancer, P = 0.0001
(B).
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In this study, I examined integrin β4 expression in invasive breast cancers from
390 patients. This is the largest study to date of integrin β4 protein expression in human
breast cancer. Here, I found that integrin β4 is highly expressed in basal-like and HER2
positive tumors, and that it associates with tumor grade. Furthermore, I characterized
integrin β4 staining patterns in benign breast, where I found that expression is absent in
the luminal cells of benign breast tissue, but is strongly expressed in the myoepithelial
cells surrounding benign ducts.
A major finding of this study is that integrin β4 expression is elevated in HER2
positive tumors. Early studies demonstrated that integrin β4 expression correlates with
HER2 expression in breast carcinoma cell lines,30,49 and furthermore, the integrin β4
subunit has been shown to form a complex with HER2 that can amplify HER2
signaling.27 However, in patient-derived tissues, the relationship between integrin β4 and
HER2 expression is controversial.50-53 The Mercurio group analyzed breast cancer gene
expression datasets using linear regression but did not find a positive correlation
between ITGB4 and HER2 mRNA expression.50 The same group also analyzed patientderived tumors using immunohistochemistry, but again was unable to demonstrate a
relationship between integrin β4 and HER2 protein expression.50 I analyzed expression
of the integrin β4 in 72 HER2 positive tumors from two different patient cohorts where I
found that integrin β4 levels were elevated in HER2 positive tumors when compared to
hormone receptor positive tumors. While these data provide further evidence for a
possible relationship between HER2 and integrin β4, study of additional cohorts will be
necessary to make a definitive determination.
A second important finding in this study is that integrin β4 expression is elevated
in TNBCs. TNBC is the most aggressive breast cancer subtype and it carries a
particularly poor prognosis. In this study, integrin β4 expression levels were highest in
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TNBC. This observation may be partially explained by the fact that many TNBCs are
immunohistochemically and phenotypically similar to myoepithelial cells, which have
very high expression of the integrin β4. The finding that integrin β4 is highly expressed
in TNBC is not surprising given its association with other high-grade, aggressive cancers
such as lung SCC (Chapter 3) and glioblastoma (Chapter 4).
Microglandular adenosis is a rare but benign breast lesion that is characterized
by a proliferation of small glands infiltrating through the stroma. 214 This lesion can be
mistaken for invasive breast cancer due to its infiltrative appearance and because it
often produces a mass.214 We identified an incidental case of microglandular adenosis in
the BTG TMA, and interestingly, the infiltrating glands were strongly and diffusely
positive for expression of the integrin β4. Recently, a number of studies have suggested
that microglandular adenosis may be a precursor lesion to invasive TNBC. Specifically,
one group identified a pattern of recurrent gains and losses (2q+, 5q-, 8q+, and 14q-) in
microglandular adenosis which is similar to that observed in basal-like breast cancer.215
Further investigation will be needed to determine whether integrin β4 plays a role in
microglandular adenosis and the transition to invasive breast cancer.
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CHAPTER SIX: SUMMARY AND FUTURE DIRECTIONS
Summary
The purpose of this study was to examine integrin α6β4 expression as it relates
to clinical variables and patient outcomes in aggressive human malignancies.

The

hypothesis of this study was that in tumors of the lung, breast, and central nervous
system, integrin β4 overexpression associates with aggressive behavior and reduced
survival. In order to study integrin α6β4 protein expression in patient-derived tumors,
tissue

microarrays

were

constructed

and

sections

were

stained

using

immunohistochemistry for the integrin β4 subunit. Integrin β4 mRNA levels in patientderived tumors were also examined using external gene expression datasets. I found
that integrin β4 expression was elevated in a subset of NSCLCs, and that
overexpression associated with pathologic features. Specifically, integrin β4 was highly
expressed in squamous cell carcinoma, and overexpression associated with venous
invasion. Elevated integrin β4 protein and mRNA expression were also associated with
decreased overall survival in patients with NSCLC. In gliomas, integrin β4
overexpression was associated with tumor grade, and was also an adverse prognostic
marker. Furthermore, integrin β4 expression was reduced in gliomas with mutations in
IDH1, thus partially explaining the better prognosis observed for IDH1 mutant tumors. In
breast cancer, integrin β4 expression was found to be highest in triple negative tumors,
and elevated integrin β4 expression was associated with HER2 overexpression and
tumor grade. In summary, I have shown that integrin β4 expression is elevated in a
number of human malignancies, and that its expression associates with tumor
aggressiveness and patient prognosis.
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Future Directions
&DQWKHLQWHJULQȕEHDWKHUDSHXWLFWDUJHW"
Integrins have been the target of a variety of therapeutic agents, and notably,
abciximab, eptifibatide and tirofiban, all of which target the integrin αIIbβ3, are important
anti-platelet agents in clinical use.216 Thus far, attempts at targeting integrins in cancer
have been less successful, though cilengitide, an inhibitor of the αvβ3, αvβ5 and α5β1
integrins demonstrated modest success in early clinical trials. 199,200,217 The αvβ3 and
αvβ5 integrins have been implicated in tumor-induced angiogenesis, an important
mechanism of tumor growth and survival.196 Results of a phase II trial of cilengitide
combined with chemoradiation therapy in patients with the brain tumor glioblastoma
(NABTT 0306) demonstrated a modest improvement in median survival (19.7 months)
when compared to patients in the EORTC trial of temozolomide and radiation therapy
(14.6 months).169,200 In addition, a recent phase II clinical trial of cilengitide as a secondline treatment for patients with advanced lung cancer found that at a dose of 600 mg/m 2,
median progression free survival was similar to that of patients treated with the current
standard of care, docetaxel.218 Importantly, in this limited phase II clinical trial, cilengitide
was associated with fewer grade 3/4 treatment-related adverse events as compared to
docetaxel.218 These findings suggest that integrin targeting may be an efficacious and
potentially safe treatment for cancer patients. Interestingly, a function-blocking antibody
to the integrin α6 subunit has also been developed, and treatment with this antibody was
able to halt the progression of osteolytic metastases in a xenograft model of metastatic
prostate cancer.219
While targeting the α6β4 integrin may be difficult due to the necessity of this
integrin for integrity of the epithelial-mesenchymal junction, it may be possible to target
the cytoplasmic signaling domain of the integrin β4 subunit in order to prevent invasive
and proliferative signaling.77 Notably, mice carrying a targeted deletion of the β4
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cytoplasmic signaling domain develop smaller and less vascularized tumors than wildtype controls upon subcutaneous tumor implantation.5 This targeted deletion has also
been introduced into a mouse model of mammary carcinoma (MMTV-Neu), where mice
with the targeted deletion exhibit impaired tumor growth and metastases compared to
controls.27 It has been suggested that targeting of the integrin α6β4 could lead to severe
adverse effects such as skin and mucosal blistering. However, in normal epithelial
tissues, the integrin β4 is present only at the basal aspect of cells where they are bound
to the extracellular matrix, thus protecting this integrin from targeted therapies in normal
cells. However, during carcinoma progression, the integrin β4 is released from
hemidesmosomes and relocalized over the entire cell surface where it can be more
easily targeted. This change in integrin localization and binding may make it possible to
preferentially target integrin β4 in malignant cells. Targeting could be accomplished
using monoclonal antibodies, small molecule inhibitors, or through nanoparticle delivery
systems that recognize and bind to the integrin β4.

Where does the integrin β4 fit in with molecular subtypes of TNBC?
As was previously described, the major molecular classification scheme for
breast cancer divides tumors into Luminal A, Luminal B, HER2 enriched, and basal-like.
Additional subtypes including claudin-low and normal-like have also been described.220
In addition to these classification schemes, the Pietenpol group has developed a
molecular classification scheme specifically for TNBC.221 This classification includes the
following subtypes: basal-like 1, basal-like 2, immunomodulatory, mesenchymal,
mesenchymal stem-like, and luminal androgen receptor.221 As these TNBC subtypes
demonstrate unique chemosensitivity pattens and clinical outcomes, we would like to
determine which of these specific subtypes display integrin β4 overexpession. This will
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help further delineate the role of integrin β4 in specific subtypes of breast cancer, and
will allow for further mechanistic studies within specific molecular subtypes.

What is the role of the integrin β4 in the cancer stem cell population?
In benign epithelia, integrin β4 is expressed in basal progenitor cells. For
example, integrin β4 expression is strong in the basal cells of stratified squamous
epithelium222 and in the basal cell layer of bronchial epithelium (Chapter 3). The binding
partner for the integrin β4 subunit is the integrin α6 subunit (CD49f), a known mediator of
stem-cell like properties in breast cancer.223 However, the role of integrin β4 in cancer
stem cells remains unclear. I have shown that integrin β4 expression correlates with the
expression of stem-cell markers such as CD44, and furthermore, we have demonstrated
that integrin β4 is upregulated in the glioblastoma cancer stem-cell population
(unpublished data). In breast cancer, expression of the integrin β4 is highly correlated
with expression of FOXC1, a transcription factor implicated in cancer stem-cell
development. Further investigations will be needed to clarify the role of the integrin β4 in
the cancer stem cell population.
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